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Abbreviations: 
 HMG-CoA R, 3-hydroxy-3-methylglutaryl-coenzyme A reductase; 
 3α-diol, 5alpha-androstane-3alpha, 17beta-diol;  
 3β-diol, 5alpha-androstane-3beta, 17beta-diol;  
 7α-OH, 7α-hydroxycholesterol;  
 7β-OH, 7β-hydroxycholesterol;  
 7-keto, 7-ketocholesterol;  
 24(S)-OH, 24(S)-hydroxycholesterol;  
 27-OH, 27-hydroxycholesterol;  
 5a-DHP, 5a-dihydroprogesterone;  
 5a-DHT, 5a- dihydrotestosterone 
 3b-diol, 3b-androstenediol 
 3a-diol, 3a-androstenedio  
 17b-E, 17b-Estraiol; 
 17a-E, 17a-Estraiol; 
 P450scc, cytochrome P450 side chain cleavage;  
 ACN, Acetonitrile; 
 AD, Alzheimer disease 
 APOE, apolipoprotein E;  
 ABCA1, ATP-binding cassette A1;  
 ABCG1, ATP-binding cassette G1;  
 CL, cardiolipin;  
 CE, cholesterol ester; 
 CER,Ceramides; 
 CPS1, carbamoyl-phosphate synthase 1 
 CTRL, non-diabetic rats;  
 DG, diacylglycerol ; 
 DHA, Docosahexaenoic acid 
 DHEA, dehydroepiandrosterone;  
 DRG, dorsal root ganglia; 
 ELOVL, elovl fatty acid elongase 5 
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 FAs, fatty acids; 
 GC, gas chromatography; 
 HCl, chloridric Acid; 
 HSL, hormone-sensitive lipase;  
 IDDM, insulin dependent diabetes mellitus; 
 ISOPREG, 3b,5a- Tetrahydroprogesteroide ;  
 Lc, lung cancer; 
 LC, liquid chromatography 
 LC–MS/MS, liquid chromatography–tandem mass spectrometry;  
 LDLR, low density lipoprotein receptor;  
 Lyso-PLs, lysophospholipids, 
 LysoPC, lysophosphatidylcholines; 
 MeOH, methanol; 
 MG, glycerolipids monoacylglycerol; 
 MS, multiple sclerosis; 
 NIDDM,  non-insulin dependent diabetes mellitus; 
 NCV, nerve conduction velocity; 
 PREG, pregnenolone;  
 PROG, progesterone;  
 PLs, phospholipids;  
 PA, phosphatidic acid, ; 
 PC,phosphatidylcholine  
 PE, phosphatidylethanolamine; 
 PG. phosphatidylglycerol; 
 PI. phosphatidylinositol; 
 PS, phosphatidylserine; 
 SUL,Sulfatidis; 
 PUFAs, n-3 polyunsaturated fatty acid; 
 SCAs, Spinocerebellar Ataxias; 
 SIM/SIM, selective ion monitoring; 
 SM.  Sphingomyelin; 
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 SNC, central nervous system; 
 SNP, peripheral nervous system; 
 SREBP, sterol regulatory element-binding protein ;  
 StAR, steroidogenic acute regulatory protein;  
 SOAT1, sterol O-acyltransferase 1;  
 STZ, streptozotocin; 
 T, testosterone 
 TG, triacylglycerol 
 THP, tetrahydroprogesterone;  
 TSPO, translocator protein- 18 kDa; 
  
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2.1 INTRODUCTION 
 
Lipids are a very heterogenic class of biomolecules with a wide range 
of structures and functions. In 2005, the International Lipid 
Classification and Nomenclature Committee on the initiative of the 
LIPID MAPS Consortium developed and established a comprehensive 
classification system for lipids based on well-defined chemical and 
biochemical principles and using a framework designed to be 
extensible, flexible, scalable and compatible with modern 
informatics technology. On this basis the lipids are defined as 
hydrophobic or amphipathic small molecules that may originate 
entirely or in part by carbanion based condensations of ketoacyl 
thioesters and/or by carbocation based condensations of isoprene 
units  Based on this classification system, lipids have been divided into 
eight categories: fatty acyls, glycerolipids, glycerophospholipids, 
sphingolipids, saccharolipids and polyketides (derived from 
condensation of ketoacyl subunits); and sterol lipids and prenol lipids 
(derived from condensation of isoprene subunits). (Fahy et al., 2011). 
The term lipidome refers to the complete profile of lipid species 
present in cell, organelle, tissue or body fluid, while lipidomics has 
been defined as the study of cellular lipidomes in biological systems 
including the complete characterization of lipid molecular species 
and the comprehension of their biological roles (Gross et al., 2011; 
Wenk, 2010). In the last years, lipidomics has emerged as an 
extremely valuable tool for biosciences. An increasing number of 
research paper are focused towards experimental protocols 
mapping the lipidome of biological models to better understand the 
role of lipid in the different pathway or pathologies.  
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2.2 ROLE OF THE LIPIDS IN THE NERVOUS SYSTEM  
 
The lipids are fundamental constituents of the nervous tissue to 
guarantee physiological function, such as in myelin, in the plasma 
membrane of neurons where they have regulatory functions. In 
particular, have been identified steroids, cholesterol and its 
derivatives, fatty acids and its metabolites such as prostaglandins, 
endocannabinoids.  
Myelin sheaths represent a highly specialized form of plasma 
membrane present in the central and peripheral nervous system. The 
myelin sheaths are enriched in lipids and in according to recent 
paper, the lipidome human of central nervous system (CNS) myelin 
consists of about 700 different lipids, majority known and classiﬁed like 
phosphatidylcholines, phosphatidylethanolamines, sphingomyelins, 
cerebrosides, sulfatides and they represent 60%, while the remaining 
species have not been previously associated with myelin. The mainly 
components that are present in myelin are cholesterol, 
glycerophospholipids and glycosphingolipids with a molar ratio well 
defined (4:4:2). Similarly, lipid to protein ratio is maintained at about 
1:1 in CNS myelin and 5:1 in peripheral nerves. Qualitative or 
quantitative alterations of these ratios are associated with myelin 
defect (Gopalakrishnan et al., 2013).  
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2.2.1 CHOLESTEROL, OXYSTEROLS AND NEUROACTIVE STEROIDS. 
 
Defects in lipid homeostasis in the central nervous system (CNS) o 
peripheral nervous system (PNS) lead to structural and functional 
alterations affecting different pathway (i.e. cholesterol biosynthesis, 
fatty acid biosynthesis). The brain represents the most cholesterol rich 
organ; in the cerebral tissue, cholesterol is necessary for both cell 
functions and membrane structure of neurons and glial cells. Similar 
to other tissues in the brain, the cholesterol homeostasis is regulated 
by LXRs, whose activation induces the expression of a plethora of 
genes involved in cholesterol efflux. (Cermenati et al., 2013).  
Liver X Receptors (LXR) are members of the nuclear receptors family. 
LXR have the classical structure of a nuclear receptor: a DNA binding 
domain, a ligand binding domain, and a ligand independent 
activation function 2 that, through the recruitment of coactivators 
and corepressors, regulate the activity of the receptor.  LXR natural 
ligands are represented by oxysterols, an oxidized form of cholesterol 
produced from the cells as intermediates in steroid hormones or bile 
acids biosynthesis (Janowski et al., 1996). In according to the nature 
of the physiological ligands, LXR play an important role in cholesterol 
and lipid metabolism. 
The brain’s cholesterol is mainly present in myelin and low cholesterol 
levels in CNS results in reduced myelination in oligondedrocytes. Thus, 
the maintenance of cholesterol homeostasis is crucial in the CNS. On 
the other hand, high cholesterol levels can lead to detrimental 
effects (Saher et al., 2005). 
Alterations in cholesterol metabolism in the SNC are linked to several 
diseases such as Alzheimer’s disease, Parkinson disease, Multiple 
sclerosis (Cai et al., 2012; Teune et al., 2014).  
Cholesterol is the precursor of signaling molecules or hormones such 
as neuroactive steroids and oxysterols. In the nervous system 
15 
 
 
neuroactive steroids exert their action by activating gene 
transcription, through the classic nuclear receptor-dependent 
mechanism involving different signaling pathways (Nadal et al., 2001; 
Melcangi and Panzica, 2006). 
Several studies have highlighted the important roles of neuroactive 
steroids in the control of central nervous system functions during 
physiological and pathological conditions, suggesting that they may 
represent good candidates for the development of protective 
strategies against neurodegenerative and psychiatric disorders. In 
fact neuroactive steroid levels are modified by neurodegenerative 
conditions (i.e., Alzheimer’s and Parkinson’s diseases, multiple 
sclerosis) or by mental diseases (i.e,. schizophrenia) and may have an 
important role in physiological conditions, as the reorganization of 
grey and white matter during human puberty (Luchetti et al., 2011). 
Oxysterols are a class of cholesterol and represent important 
intermediates in a number of hepatic and extrahepatic metabolic 
pathways. The term “oxysterol” was used to refer to derivatives of 
cholesterol obtained by introduction of a hydroxyl group in the 
molecule by autoxidation or by action of speciﬁc monooxygenases 
(Crosignani et a., 2011). The conversion of cholesterol into bile acids 
follows different pathways and starts enzymatically from the 
introduction of a hydroxyl group in different cholesterol positions 
giving origin at 24S-hydroxycholesterol, 7α-hydroxycholesterol 27-
hydroxycholesterol and 25-hydroxycholesterol (Crosignani et a., 
2011). The biological role of oxysterols under physiological conditions 
is strictly related to the entire cholesterol metabolism, ranging from 
regulation of cholesterol synthesis to regulation of cholesterol 
elimination through bile acid synthesis (Javitt NB.,2002). Also, 
cholesterol uptake and cholesterol transport are inﬂuenced by the 
signaling pathways between oxysterols and individual proteins, such 
as liver X receptor (LXR) (Javitt NB.,2002). One of the most important 
16 
 
 
enzymatic derived cholesterol is 24S-hydroxycholesterol. The 
conversion of cholesterol in 24S-hydroxycholesterol is the only way to 
eliminate excess cholesterol from brain (Bjorkhem I, 2006). Recent 
papers have investigated oxysterols in different animal model. 
Altered levels or distribution of oxysterols in brain areas have been 
associated with several neurodegenerative diseases (Jeitner et 
al.,2011) supporting that these molecules play crucial role in signaling 
function. J.L. Goldstein et al have demonstrated as the oxysterol 
negatively influence the regulation of cholesterol biosynthesis (J.L. 
Goldstein et al.,2006). 
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2.2.2 FATTY ACIDS  
 
Fatty acids (FAs) represent another important component widely 
diffused in all living organisms. They are essential as substrate in both 
CNS and PNS for the synthesis of more complex lipids such as 
glycerophospholipids, cerebrosides, gangliosides and for post 
translational modification of proteins.  
The role of fatty acids as a mitochondrial substrate for ATP production 
and as an inhibitor of pyruvate dehydrogenase has been 
investigated since the 1960s, and it is now well described (Lopaschuk 
et al., 2010). Fatty acid regulation of gene expression via activation 
of various nuclear receptors was extensively studied over the past 30 
years, and it is now well established that stimulation of peroxisome 
proliferator-activated receptors up-regulates the expression of genes 
involved in mitochondrial fatty acid metabolism (Madrazo et al., 
2008). In particular, dietary fatty acids affect the composition of 
mitochondrial phospholipids, which in turn impacts mitochondrial 
function. Mitochondrial dysfunction plays a causal role in different 
pathologies, such as heart failure, neurodegenerative disorders and 
diabetes. Thus, there is great interest in understanding how dietary 
long chain fatty acids can be used to prevent or reverse 
mitochondrial dysfunction in human disease. Supplementation with 
n-3 PUFA increases membrane phospholipid DHA and depletes 
arachidonic acid, and can increase cardiolipin, a tetra-acyl 
phospholipid that is unique to mitochondrial and essential for optimal 
mitochondrial function (Stanley et al., 2012). Cardioprotection 
observed in pathological states such as heart failure may be due in 
part to mitochondrial phospholipid remodeling and improved 
mitochondrial function (Stanley et al., 2012).  
 In recent years, polyunsaturated fatty acids like DHA have gained 
much attention due to promising results in a number of 
18 
 
 
neurodegenerative conditions (Hacioglu et al., 2012; Yassine et al., 
2017). In this contest, several studies have demonstrated that oral 
intake DHA improves cognitive performance and protecting against 
synaptic degeneration (Lim et al 2005; Green et al 2007). 
Moreover, polyunsaturated fatty acids are required for the normal 
development of the central nervous system. The PLs containing ω-3 
PUFAs seem to provide beneficial effects towards inflammation 
related disorders through specific mechanisms and a plethora of 
bioactivities including their ability to modulate the eicosanoid 
pathway (Burri et al 2012; Hishikawa, et al 2017; Murray et al 2015). 
These PLs include plasmalogens, PLs and PL carriers of FA precursors 
of eicosanoids (Tessaro et al 2015; Reis 2017).  It has been 
demonstrated that when ω-3 PUFAs (such as EPA and DHA) are 
constituents of membrane phospholipids (PLs), they are more 
efficiently incorporated into tissue membranes (Bazan., 2007). 
Indeed, long chain polyunsaturated fatty acids, such as arachidonic 
acid, and various ω-3 fatty acids, like docosahexaenoic acid and 
eicosahexenoic acid, are commonly found at the sn-2 position of 
glycerophospholipids and represent the substrates for the synthesis of 
classical (prostaglandins leukotrienes, thromboxanes, lipoxins) and 
nonclassical eicosanoids (endocannabinoids, neuroprotectins and 
resolvins) (Bazan, 2007).  
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2.3 NEUROPROTECTIVE ACTIVITIES OF LIPIDS  
 
As mentioned above, alteration of lipid metabolism or homeostasis is 
the cause of some neurodegenerative diseases such as Alzheimer's 
disease, Huntington's disease, Parkinson's disease, diabetes-
associated cognitive loss, as demonstrated in animal models and 
human subjects (Vance, 2012; Cai et al., 2012; Teune et al., 2014).  
In addition, alterations of lipid profile in both CNS and PNS myelin 
are observed in model of peripheral neuropathy (Cermenati et 
al., 2012) 
In principle, restoration of lipid species to physiological levels and 
composition could represent a direct and simple goal of therapeutic 
strategies. Notably, some lipid species such as n-3 PUFAs beneﬁcially 
affecting the brain functions, are commonly present in the diet, 
hence consumption of foods enriched or supplemented with n-3 
PUFAs could represent an alternative strategy for prevention of 
neurodegenerative disorders. This field has received great attention 
and a high number of studies have been published in latest years 
(Figueroa et al., 2013; Zárate et al., 2017). Nevertheless, strong 
evidences of neuroprotective effects by dietary n-3 PUFAs in 
randomized controlled trials are still lacking (Gillette et al., 2013; 
Agostoni et al., 2017).  
Low blood levels of DHA and EPA have been shown to be associated 
with ADHD symptoms such as inattention and hyperactivity (Crippa 
et al., 2016). Based on this evidence, an increasing number of 
intervention studies have been conducted to evaluate the efficacy 
of ω-3 PUFAs supplementation for the treatment of children with 
ADHD (Crippa et al., 2016). 
To concern neuroactive steroids several studies have demonstrated 
the protective action of these molecules in peripheral neuropathy 
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associated with pathological condition (Melcangi et al., 2006; 
Cermenati et al., 2017).  
Diabetes is one of the major causes of peripheral neuropathy 
therefore the protective effects of neuroactive steroids have 
been investigated in deep. It has been demonstrated in several 
studies that diabetes-induced peripheral neuropathy in animals is 
characterized by reduced levels of neuroactive steroids in both CNS 
and PNS and unbalanced fatty acid pattern (Caruso et al., 2008; 
Cermenati et al., 2012;) The restoration of neuroactive steroid levels 
could represent a possible therapeutic approach, also applicable to 
humans. Indeed, promoting steroidogenesis, by increased cholesterol 
translocation into mitochondria or by acting on cholesterol 
metabolism, translates into improvement of neuropathy in diabetic 
animals (Giatti et al., 2009; Cermenati et al., 2010). Given the role of 
lipids in CNS and PNS, lipid lowering therapies could in principle affect 
the brain homeostasis and peripheral myelin function.  
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2.4 SEX DIMORPHISM IN LIPIDOMIC   
 
Experimental evidence underlines that sex is one of the most relevant 
biological variables significantly influencing lipidomic profiles.  For 
many years, the researchers have considered the estrous cycle a 
confounding variable rather than a parameter to better understand 
the differences between the sex (Shansky et al., 2016). Sex speciﬁc 
lipidomics and genomics integration represents a powerful tool to 
understand gene regulation.   
Mittelstrass et al., (2011) have found a correlation between a single 
nucleotide polymorphism in carbamoyl-phosphate synthase 1 (CPS1) 
locus in plasma of patients affected by coronary artery diseases 
(CD). Specifically, he has been demonstrated a significant difference 
in 102 out of 131 metabolites between males and females, namely 
sphingomyelin (SM, C22:2-OH), several lysophosphatidylcholines 
(LysoPC), phosphatidylcholines (PC) and acylcarnitines. (Mittelstrass 
et al., 2011). Plasma sphingolipids levels were associated with an 
increased risk of cardiovascular events in subject affected by type 2 
diabetes as reported in Alshehry et (2016).  
Alteration of the lipids in cancer is related with a sexual dimorphysm 
(Guo, et al., 2012). Specifically, differences in plasma levels of lipid as 
phosphatidilcoline (PC) (C34:2), PC (C36:3) and PC (C36:2), in 
females affected by lung cancer (Lc) compared to LC males, are 
detected (Guo, et al., 2012). These different sex metabolic behaviors 
could imply different clinical treatments for the lung cancer in 
females and males in the future. In addition, these results strongly 
indicated that the serum metabolites found in this study may have 
great clinical potential in early prognosis and progression of Lc (Guo 
et al., 2012).  
Lipidomic studies in mice have also allowed to understand the 
metabolic mechanisms underlying CNS pathophysiological 
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conditions. For instance, lipidomic analysis in an Alzheimher disease 
mouse model showed sex- related diﬀerences of several metabolites. 
Speciﬁcally, Gonzales- Dominguez and collaborators, studying 
peripheral tissues, such as liver and kidney in AD mouse model, have 
found several alterations in various lipid species such as PC, PE, 
plasmalogens, phosphoinositols, phosphoserines, phosphoglycerols 
and lysophospholipids (Gonzales- Dominguez R. et al., 2015). These 
results, compared with those obtained in another study by Rappley 
and collaborators, who showed a greater decrease of LysoPC (C22: 
6) in males than in females confirm the relation between the sex and 
changes in the brain lipidome (Rappley et al, et al., 2009). 
Lipidomic studies in mice have also allowed to understand the 
metabolic mechanisms underlying CNS pathophysiological 
conditions. Speciﬁcally, Gonzales- Dominguez R. and collaborators, 
studying peripheral tissues, such as liver and kidney in AD mouse 
model, have found several alterations in various lipid species such as 
PC, PE, plasmalogens, phosphoinositols, phosphoserines, 
phosphoglycerols and lysophospholipids (Gonzales- Dominguez R. et 
al.,2015). These results, compared with those obtained in another 
study by Rappley and collaborators, who showed a greater 
decrease of LysoPC (C22: 6) in males than in females confirm the 
relation between the sex and brain lipidome (Rappley et al., 2009).  
In this contest, neuroactive steroids play an important role; sex 
diﬀerences have been observed in the incidence of psychiatric and 
neurodegenerative disorders. For instance, as reported in the acute 
phase of experimental autoimmune encephalomyelitis model (an 
experimental model of MS), male rats showed decreased levels of 
PREG and PROG in the cerebral cortex and cerebellum and 
increased levels of THP in the cerebral cortex and spinal cord. 
However, these changes in steroid levels did not occur in female rats 
(Giatti et al., 2010). 
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Finally, lipidomic studies oﬀer a powerful tools and therapeutic 
strategies useful for the integration with other omics data (i.e, 
transcriptomics and proteomics) to better understand 
pathophysiological mechanisms. In this context, the characterization 
of sex, age and race-related features among different population or 
during distinct phases of development and aging is now considered 
extremely relevant for the attainment of personalized therapeutic 
approaches. 
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3. MASS SPECTROMETRY 
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3.1 INTRODUCTION 
 
Mass spectrometry is an essential analytical tool in all fields of 
sciences. It is used to analyze combinational data, sequences of 
biomolecules, to explore single cells and for quality control of drugs 
(De Later et al., 2006; Budzikiewicz et al., 2006;).  
The basic principle of mass spectrometry is to measure the mass to 
charge ratio (m / z) of ions. The first step in the mass spectrometric 
analysis of compounds is the ion source. Then in the analyzer these 
ions will be manipulated and separated according to their mass to 
charge ratio. Finally, the detector detects the m / z and the 
abundance of each ion population. Thank to tandem mass 
spectrometry, It is easily used to elucidate the structure and chemical 
properties of molecules and complex. Due to its sensitivity, its 
selectivity and its ability to perform rapid analyzes, mass spectrometry 
plays an important role in all sciences.  
Lipidomics, defined as the large-scale study of cellular lipids (i.e., the 
lipidome), has recently emerged as a rapidly expanding research 
field: the systems biology (Han X et al.,2003). In the development of 
lipidomics study, mass spectrometry is the leading techniques in the 
characterization, identification, and quantitation of lipids.  
Lipidomics, as the metabolomics, could be classified in Untargeted 
and Targeted approaches.  
Lipidomic profiling studies the lipidome in a holistic approach and 
from a point of limited a priori biological knowledge. The study is 
designed so to acquire data on a large subset of metabolites 
followed by interrogation of these data to define biological 
differences. Data interrogation is performed with the application of 
univariate and multivariate analysis tools. These are discovery-phase 
studies, otherwise referred to as hypothesis-generating or inductive 
sometimes by the non-cognoscenti as a ‘fishing expedition’ and 
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have the goal to discover new biology or biomarkers. Untargeted 
approaches allow that a huge number of metabolites can be 
measured. To this end, different lipidomics-based platforms have 
been developed and extensively used to analyze diverse pathways 
and networks associated with lipid metabolism, trafficking, and 
homeostasis.  
The second approach of MS techniques focuses on the “targeted” 
lipidomic analysis of one or a limited number of lipids. The lipidome 
targeted analysis is driven from known biology, where a limited 
number of metabolites are characterized and biochemically known 
with biological importance at the start of the study before data 
acquisition is performed. Quantification of the metabolites is 
performed through the use of internal standards and authentic 
standards for the preparation of calibration curves for each of the 
metabolite. LC-MS and LC-MS/MS based methods have been 
extensively utilized for this purpose.  
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3.2 MASS SPECTROMETRY IN LIPIDOMICS 
 
3.2.1 TECHNIQUE AND APPROACH IN LIPIDOMIC STUDY 
 
As described above, the main strategies used for lipidomics 
approaches are “untargeted lipidomics” and “targeted lipidomic”. 
One of the important steps in a lipidomic experiment is represented 
by sample collection and preparation for the analysis (Haukaa et al., 
2016). The optimization of sample extraction procedures must 
guarantee experimental reproducibility, precision, accuracy for the 
best quality of the analysis. Therefore, the extraction method should 
be chosen depending on the type of lipidomic approach. Indeed, 
for “untargeted approach" a minimal or no sample preparation 
should be emplayed to avoid loss of metabolites from the biological 
samples. On the other hand, “targeted approach” requires a specific 
extraction and puriﬁcation method of selected metabolites should 
be carried out (Astarita et al., 2013). In addition, another parameter 
that should be considered is the nature of metabolites. They can be 
grouped in water soluble or hydrophilic compounds and in water 
insoluble or hydrophobic compounds, requiring diﬀerent extraction 
procedures. 
Several works report a simple procedure to extract lipids and 
hydrophilic metabolites with a single method. These protocols is able 
to separate and recover the water soluble and lipid metabolite 
fractions by adding to samples a mixture of chloroform:methanol 
(1:1, v/v) or chloroform:- water (2:1, v/v), followed by vortex-mix and 
then centrifugation. Subsequently, a phase containing polar 
metabolites (upper phase) and a phase containing lipids (bottom 
phase) are obtained (Paglia et al., 2017). After the extraction 
protocol, it is common to perform a sample pretreatment step before 
carrying out the analysis. Gas chromatography (GC) or liquid 
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chromatography (LC) coupled to mass spectrometry (MS) allow the 
simultaneous acquisition and, if any, quantiﬁcation of metabolites 
with high speciﬁcity, resolution and in most cases with high-
throughput capacity. 
Mass spectrometers with atmospheric pressure ionization source (API) 
such as electron spray ionization (ESI) and atmospheric pressure 
chemical ionization (APCI) were used. ESI is a soft ionization 
technique used in mass spectrometry that uses an electrospray 
produced by applying an electric field to the eluent forced to pass 
through a capillary to create a fine aerosol from which ions are 
formed by desolvation. Soft ionization refers to the processes which 
imparts little residual energy onto the subject of molecules and as a 
result in little fragmentation. APCI does not generate multicharged 
ions and does not produce (or in a very small amount) fragmentation; 
it operates at higher temperatures and is commonly used to analyze 
polar and nonpolar compounds of relatively low molecular weight 
and thermostable. The principle of APCI is to ionize the primary ions 
(produced from the gas in the atmosphere, such as nitrogen, and 
oxygen); these ions exchange the charge with solvent molecules that 
in turn exchange with the analytes, the reactions are carried out at 
atmospheric pressure. Usually, APCI is less sensitive compared to ESI, 
but for polar compounds such as lipids, it may offer some advantages 
over electrospray. 
However, it is extremely challenging to identify large numbers of lipids 
from MS experiments of biological samples where analysis is 
complicated by the presence of a huge amount of interferering with 
similar mass-to-charge (m/z) ratios. 
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LIPIDS ANALYSIS 
 
in the last decades efficient improvement has been made in mass 
analyzers. The very first LC-MS was single stage quadruple (SSQ) that 
gives data on molecular ion peaks and fragment ion. However, SSQ 
has been replaced by triple stage quadruple (TSQ), Ion trap, Time of 
Flight (TOF), Hybrid Ion Trap (Q-Trap), Hybrid TOF (Q-TOF), Fourier 
Transform Inductive Couple Resonance (FT-ICR) and Orbitrap 
analyzers. In such a system, parent ion is selected and then it is 
fragmented to get complete spectrum. There are various methods 
for fragmenting molecules for tandem mass spectrometry, including 
collision-induced dissociation (CID), electron capture dissociation 
(ECD), electron transfer dissociation (ETD). 
The introduction of Ultra High-Performance Liquid Chromatography 
(UHPLC) has signiﬁcantly improved separation as well as High 
resolution mass spectroscopy (HRMS) such as Orbitrap MS, have 
allowed to detect ions with high resolution (Zhang et al., 2007). The 
data also permits the calculation of accurate mass of the 
metabolites and in determination of their molecular formula (Han et 
al., 2008).  
In addition, it’s well known, the use of mass spectrometry to quantify 
speciﬁc lipids by targeted approach (Gowda et al., 2008). MS like Q-
Trap, TSQ are designed to perform single reaction monitoring (SRM) 
and multiple reaction monitoring (MRM). MRM mode involves that 
the first analyzer allows only a single mass through and the second 
analyzer monitors for multiple user-defined fragment ions. Precursor 
ion scanning refers to monitoring for a specific loss from the precursor 
ion. thanks to this characteristic these experiments are used to 
increase specificity of detection of known molecules permitting 
detection of low levels analytes (Yao et al., 2008). 
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Recently another approach used for the determination of lipids in 
biological samples is the MS shotgun. The technique involves the 
acquisition of data by direct infusion. This approach is able to identify 
many metabolites by distinguish isobaric precursor ions and 
fragments (Sadowski et al., 2017).  
In addition, mass spectrometry imaging (MSI) is an emerging tool for 
mapping the distribution, in a label-free mode, from a thin, flat 
samples, biological tissue sections, ranging from small metabolites to 
large proteins. The ambient mass spectrometry include the 
desorption electrospray ionization (DESII, direct analysis in real time 
(DART), desorption atmospheric pressure chemical ionization 
(DAPCI), electrospray-assisted laser desorption/ionization (ELDI), 
atmospheric solids analysis probe (ASAP) and jet desorption 
ionization (JeDI) can be used as a rapid analysis tool with little to no 
sample preparation and allows repeated measurements on samples 
from different biological sources (Gowda et al., 2008; Hyotylainen et 
al., 2015). 
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3.2.2 LIPIDOMIC DATA ANALYSES 
 
The large amount of data obtained from a lipidomic analysis requires 
tools to manage results in a clear and unequivocal way. The choice 
of the appropriate chemometric methods is essential to extract 
valuable information from the crude data as well as to allow the 
interpretation of the lipidomic results. Because of the wide set of data 
generated, the study of lipidomic data use statistic particular 
methods. There are different approaches to apply: from the 
application of univariate tests for the comparison of two populations 
(i.e., control vs. treated) to the multivariate tests.  
The most used tool in the treatment of lipidomic data is the analysis 
of hypothesis testing the difference between two groups of samples, 
distribution of the population or correlation between variables (t-
tests) (Checa et al., 2015). Depending on the assumptions about the 
probability distribution of the data, statistics could be parametric 
(based on assumptions about the parameters of probability 
distributions) or nonparametric (without these assumptions regarding 
the distribution) (Checa et al., 2015). 
Analysis of Variance (ANOVA) is a family of statistical models that can 
be used to separate and estimate the different causes of variation. 
ANOVA is used to provide a statistical test for the equality of the 
means of several groups and it can be seen as a generalization of 
the t-test to more than two groups (Miller et al., 2010). Millet explains 
as different ANOVA approaches can be considered: from the 
classical one-way ANOVA (a single measured variable and one 
factor) to two-way ANOVA (a single measured variable and more 
than one factor). In this case, more information can be obtained as 
not only significance of the factors is tested but also the interaction 
between them (in this case replicates of the measurements are 
needed) (Miller et al., 2010). 
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The most explorative multivariate method used is Principal 
Component Analysis (PCA). The primary goal of PCA is to explain the 
variation in the original data, defined by variables called principal 
components, which retain most of the relevant information from the 
original data. These principal components are linear combinations of 
the original variables that hierarchically describe the directions of 
maximum variation in the data without repeating information which 
is guaranteed by the orthogonality between them (Harrington et al., 
2005). Finally, even all these statistic methods are used for lipidomic 
data analysis, it is evident that a critical evaluation needs to selecte 
the best tests to apply. Before to analysis, data needs to be inspected 
to check if it fulfils the requirements of the chemometric method of 
choice.  
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4. Sterol regulatory element binding 
protein-1C knockout mice show 
altered level of neuroactive steroid 
levels in sciatic nerve 
Mitro N, Cermenati G, Audano M, Giatti S, Pesaresi M, Pedretti S, Spezzano R, 
Caruso D, Melcangi RC. J Neurochem. 2017 Aug;142(3):420-428. doi: 
10.1111/jnc.14063. Epub 2017 May 29. 
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4.1 INTRODUCTION  
 
Peripheral neuropathy is one of the most common disorders with a 
prevalence of about 2.4% that rises with aging to 8% in the general 
population. Peripheral neuropathy may be inherited, such as those 
referred to Charcot– Marie–Tooth (CMT) or acquired, for instance 
those occurring during aging process, after physical injury, in systemic 
or metabolic disorders (i.e., diabetes mellitus, vitamin deﬁciencies, 
alcoholism, kidney failure, cancer, etc.) (England and Asbury, 2004). 
In the context of PNS, it is important to highlight the role of 
neuroactive steroids, cholesterol-derived molecules that function as 
protective agents in central and peripheral nervous system (Giatti et 
al., 2010). Peripheral nerves and Schwann cells not only synthesize 
and metabolize neuroactive steroids but are also targets for these 
molecules. Classical intracellular steroid receptors, such as PROG (PR), 
estrogen, glucocorticoid, and mineralocorticoid receptors, have 
been detect (Melcangi et al., 2001; Groyer et al., 2006). In according 
to neurosteroidogenic capacity of PNS, several studies have 
demonstrated altered level of neuroactive steroid in different 
experimental models of peripheral neuropathy (Melcangi et al., 2016; 
Giatti et al., 2015). In addition, it has been observed a link between 
neuroactive steroids and FA synthesis in the PNS. LXR activation in 
diabetic peripheral neuropathy induced by streptozotocin, exert 
protective effect, restoring alteration in the levels of fatty acid and 
neuroactive steroids in sciatic nerve (Cermenati et al., 2010 and 
2012). According with this finding, it has been, demonstrated that 5a-
dihydroprogesterone (5α-DHP) and 3-alpha-diol are protective 
agents against diabetic peripheral neuropathy by regulating the de 
novo lipogenesis pathway, which positively influences myelin fatty 
acid profile and consequently improved myelin structure and 
function (Mitro et al., 2014).  
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In addition, there are evidences that peripheral neuropathy could be 
induced by deficiency of the sterol regulatory element binding 
protein-1c (SREBP-1c) (Cermenati et al., 2015). SREBP-1c is a lipogenic 
transcription factor of the basic helix-loop-helix-leucine zipper family 
that controls the synthesis of fatty acids (FA) and triglycerides (Liang 
et al. 2002). SREBP-1c belongs to the family of membrane-bound 
transcription factors, called Sterol regulatory element binding 
proteins (SREBPs). Roles of SREBPs have been established as lipid 
synthetic transcription factors for cholesterol and fatty acid synthesis. 
SREBPs are able to regulate a wide range of lipid genes. Specifically, 
several studies have highlighted that SREBP-1 is involved in both the 
metabolism of fatty acids and of insulin and glucose, while SREBP-2 is 
a regulator of the synthesis of cholesterol (Shimano, 2001). Horton et 
al have demonstrated that lack of the SREBP-1c factor induces 
alteration of the "bundle of Remak" and hypermyelination of the 
small-caliber fibers that compromise the functions of the nerves; 
peripheral nerves with a lack in the SREBP-1c show the decrease of 
the fatty acid synthesis and glycolytic flow and an accelerate 
catabolism of fatty acids and mitochondrial functions. (Horton et al., 
2002). Cermenati et al have, also, found that knock-out (KO) SREBP-
1c mice at 2 months of age shows a neuropathic phenotype with 
reduced expression of genes and altered levels of fatty acids such as 
palmitic, stearic, oleic and linoleic in the sciatic nerve (Cermenati et 
al., 2015).  
Based on these observations, to prove that neuroactive steroids and 
fatty acid synthesis are two metabolic pathways sensitive each other, 
aim of this work was to evaluate, the levels of neuroactive steroids in 
sterol regulatory-binding protein-1c (SREBP-1c) knock-out (KO) male 
mice, an experimental model of peripheral neuropathy and to 
compare with observations in wild type animals. Neuroactive steroids 
levels have been evaluated by liquid chromatography tandem mass 
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spectrometry in plasma and sciatic nerve at two and ten months of 
age (Caruso et al., 2013). These analyses were complemented by the 
gene expression profile of crucial steroidogenic enzymes in Srebf-
1cKO sciatic nerve of Srebf-1cKO and relative littermate control 
mice. 
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4.2 MATHERIALS AND METHOD  
 
All solvents and reagents were liquid chromatography–tandem mass 
spectrometry (LC-MS) grade (CARLO ERBA Reagents, Milano, Italy). 
All steroids PREG, PROG, 5a-DHP, 3a,5a-THP, 3b,5a-THP, T, 5a-DHT, 3a- 
diol, 3b-diol, dehydroepiandrosterone (DHEA), and 17b-E were 
purchased from Sigma-Aldrich, Milan, Italy. Further three internal 
standards 17b-Estradiol- 2,3,4-13C3, PREG-20,21-13C2, and PROG-
2,3,4-13C3 were used to quantitative analysis ((Sigma-Aldrich).  
 
4.2.1 ANIMALS AND REAGENTS 
 
The animals used in the experiment were purchased from The 
Jackson Laboratories, Bar Harbor, ME, USA (B6;129S6-Srebf1tm1Jdh, 
stock number: 004365) and they were bred to generate a colony of 
wild type, heterozygous and homozygous mice. All procedures were 
performed following institutional guidelines (D.L. No. 26, March 4, 
2014, G.U. No. 61 March 14, 2014) and international laws and policies 
(EEC Council Directive 2010/63, September 22, 2010: Guide for the 
Care and Use of Laboratory Animals, United States National Research 
Council, 2011). The genotyping was performed, in agreement with 
The Jackson Laboratory instructions, with the GoTaq Green Master 
Mix (Promega, Milan, Italy). To aim of the study a minimal number of 
animals was used and a F-test ANOVA analysis was applied by setting 
the effect size (f) at 0.75, the alpha error probability at 0.05, the power 
of the test ≥ 80%.  We obtained ﬁve animals per group. After the 
genotyping animals were assigned to the four experimental groups 
(wild type and SREBP-1c KO at 2 months of age and WT and SREBP-
1c KO at 10 months of age). 10 animals were used to form the wild 
type group and 10 animals for the SREBP-1cKO. Subsequently 5 
animals for genotype were arbitrarily assigned for each group. To aim 
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of the study the experiments were conducted in male mice at 2 and 
10-months of age. At 2 months of age, SREBP-1cKO animals must 
show a reduction in thermal and mechanical nociceptive threshold 
and no effect on nerve conduction velocity (early sign of peripheral 
neuropathy) compared to relative age mates. For 10-month mice: 
SREBP-1cKO male mice must show a reduction in thermal and 
mechanical nociceptive threshold and nerve conduction velocity (a 
late sign of peripheral neuropathy) compared to relative age mates. 
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4.2.2 NEUROACTIVE STEROIDS ANALYSIS 
 
Neuroactive steroids levels have been evaluated by liquid 
chromatography tandem mass spectrometry in plasma and sciatic 
nerve at two and ten months of age following the extraction protocol 
described in (Caruso et a., 2013).  
Internals standards were added to sciatic nerve tissues (15 mg for 
samples), homogenized in 2 mL of methanol (MeOH)/acetic acid 
(99:1 v/v) using a tissue lyser (Qiagen, Milan, Italy). After an overnight 
extraction at 4°C, samples were centrifuged for 5 min and the pellet 
was extracted twice with 1 mL of MeOH/acetic acid (99:1 v/v). The 
organic phases were combined and dried with a gentle stream of 
nitrogen in a 40°C water bath. The samples were resuspended with 3 
mL of MeOH/H20 (10:90 v/v) and concentrated through SPE 
cartridges, previously activated with MeOH (5 mL) and MeOH: H2O 
1: 9 v/v (5 mL), the steroids were eluted in MeOH, concentrated and 
transferred in autosampler vials before the LC– MS/MS analysis. To 
concern plasma samples, internal standards were added to 250 µL of 
plasma, were ﬁrst extracted with acetonitrile, the organic residues 
were resuspended with 3 mL of MeOH/H20 (10:90 v/v) and passed 
through SPE cartridges; the steroids were eluted in MeOH, 
concentrated and transferred in autosampler vials. 
Quantitative analysis was performed on the basis of calibration 
curves prepared and analyzed daily by positive atmospheric 
pressure chemical ionization (APCI+) using Ion Trap Mass 
Spectrometer (LTQ, ThermoElectron Co., San Jose, CA, USA) 
equipped with a Surveyor liquid chromatography (LC) Pump Plus and 
a Surveyor Autosampler Plus (ThermoElectron Co.). The mass 
spectrometer was operated in in tandem mode (MS⁄MS) using helium 
as collision gas.  
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The LC mobile phases were: 0.1% formic acid in water (phase A) and 
0.1% formic acid in MeOH (phase B). The gradient (flow rate 0.5 
ml/min) was as follows: 
 
 
 
 
 
 
 
 
Table 1: Elution gradient of the chromatographic analysis 
The Hypersil Gold column C18 (100 x 3 mm, 3 µm; ThermoElectron Co) 
was maintained at 40°C.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
minuti A% B% 
0,0 70 30 
1,5 70 30 
2,0 55 45 
3,0 55 45 
35,0 36 64 
40,0 25 75 
41,0 1 99 
45,0 1 99 
45,2 70 30 
55,0 70 30 
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Neuroactive steroids Parent 
ions 
Transitions detected CID 
17β-Estraiol (17 β -E) 255.20 133;159 35 
17α-Estraiol (17 α -E) 255.20 133;159 35 
TESTOSTERONE (T) 289.2 97;109 35 
Dehydroepiandrosterone 
(DHEA), 
271.25 197;213 35 
progesterone (PROG) 315.20 97;109 35 
5 α - dihydrotestosterone (5a-
DHT) 
291.20 255.20 35 
3 β -androstenediol(3b-diol) 257.20 121;135;147;161.20;175.20 35 
3 α -androstenedio (3a-diol) 257.20 121;135;147;161.20;175.20 35 
Pregnenolone (Preg) 299.20 159.20;199.20 35 
5 α - dihydroprogesterone 
(5a-DHP) 
299.20 189.20 35 
3 β,5 α- 
Tetrahydroprogesteroide 
(ISOPREG) 
301.20 159;173;213;227 35 
3 α,5 α -
Tetrahydroprogesteroide 
(THP), 
301.20 159;173;213;227 35 
17β estradiolo 13C3 258.00 135;162 35 
Progesterone 13C3 318.00 100;112 35 
Pregnenolone 13C4 303.00 159;175;185;203;229;243;255 35 
Table 2: ion molecular, fragment ion and collision energy of the neuroactive 
steroids under evaluation 
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4.2.3 GENE EXPRESSION ANALYSES 
 
Gene expression analysis was performed extracting mRNAs from wild 
type and Srebp-1c knockout sciatic nerves. To this aim Nucleospin 
RNA II kit (Macherey-Nagel, Duren, Germany) was used.  The gene 
expression proﬁle of the crucial enzymes involved in steroidogenesis 
was carried out with a TaqMan qRT-PCR instrument (CFX96 real-time 
system; Bio-Rad Laboratories, Segrate, Italy) using the iScriptTM one-
step RT-PCR kit for probes (Bio-Rad Laboratories). The relative 
quantification of the genes of interest was carried out by comparing 
their quantity with that of 36B4 and setting up a standard curve.  The 
gene expression analyses were performed for: 
 
P450 side chain cleavage (P450scc): enzyme responsible for the 
conversion of cholesterol to pregnenolone. 
5α-Reductase (5α-R): enzyme involved in the conversion of Progesterone 
into 5 alpha DHP and Testosterone into 5a-DHT. 
3a-hydroxysteroid oxidoreductase (3α-HSOR): enzyme necessary for the 
synthesis of 3a,5a-Tetrahydroprogesteroide (THP) and 3a-androstenedio 
(3a-diol). 
 
4.2.4 STATISTICAL ANALYSIS 
 
Comparison were obtained by two-way ANOVA, with genotype and 
age as two independent variables, followed by Bonferroni post-test. 
All statistical analyses were performed using PRISM version 5 
(GraphPad, La Jolla, CA, USA) considering a p < 0.05 as statistically 
signiﬁcant. 
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4.3 RESULTS  
 
4.3.1 NEUROACTIVE STEROID LEVELS IN SCIATIC NERVE 
 
To study the effect of the lack srebp-1c, the levels of neuroactive 
steroid (PREG, DHEA, PROG and its derivatives such as 5α-DHP, 3 α, 
5α-THP and 3β,5 α-THP, T and its derivatives such as 5α-DHT, 3α-diol, 
3β-diol and 17β-E were evaluated by LC- MS/MS in sciatic nerve and 
plasma of SREBP-1c KO and WT animals 2 and 10 months old. The 
validation of the method and transition used were previously 
described (Caruso et al., 2013). To have better sensitivity LC analysis 
was divided into three time windows: in the ﬁrst one (13C-estradiol as 
internal standard) four analytes are eluted: 17α-E, 17β-E, T and DHEA; 
in the second one PROG, 5α-DHT, 3α- and 3β- diol are eluted using 
13C-progesterone as internal standard, in the last window the 
quantiﬁcation of PREG, 5α-DHP, 3α,5α-THP, and 3β,5α-THP was 
obtained with 13C-pregnenolone as internal standard. (Caruso et al., 
2013). 
 
A)                                            B)                                    C) 
  
Fig.1: A)1° segment analysis; B) 2° window; C) the last segment in the analysis. 
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Fig.2: calibration curve of 3 neuroactive steroids evaluated 
 
In the table 3, anova analysis has revealed a significant effect of 
genotype on the levels of PREG (p<0.001), PROG (p<0.001) and its 
metabolites 5α-DHP (p<0.001) and 3α,5α-THP (p<0.05). In the case of 
PREG levels, a significant effect of age and their interaction was also 
observed (p<0.001).  
 
Table 3: The effects of age, genotype, and their interaction in sciatic nerve 
of SREBP-1c KO and WT animals. The effects have been analyzed using the 
two-way ANOVA *p < 0.05; **p < 0.01, and ***p < 0.001  
 
Bonferroni post-test has indicated that the levels of PREG depends on 
the age of the animals.  
As shows in figure 3, at 2 months of age the levels of PREG are 
signiﬁcantly higher in comparison to those observed in WT animals 
while lower levels of PREG was observed.  
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Fig.3: The levels of Pregnenolone (PREG), progesterone (PROG) and its 
derivatives in sciatic nerve of wild type (WT, blue bars) and sterol regulatory-
binding protein-1c (SREBP-1c) knock-out (KO, red bars) mice at 2 and 10 
months of age. Data are expressed as pg/mg tissue ± SEM. Bonferroni post-
test: *p < 0.05; **p < 0.01, and ***p < 0.001 versus WT (n = 5 for each 
experimental group) 
 
Changes in the concentration of PROG and 3α,5α-THP (THP) and 
3β,5α-THP (ISOPREG) were reported at 2 and 10 months of age. With 
respect to WT mice, the levels of PROG are significantly decreased 
at 2 and 10 months of age in KO group, while its metabolites 
depending on the age of the mice. Indeed, the levels of 5α-DHP and 
ISOPREG were significantly lower in sciatic nerve of KO mice at 2 
months of age, while at 10 months, a significant increase in 5 alpha 
DHP levels of SREBP-1C KO mice, THP and ISOPREG was observed in 
comparison with WT group.  
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Statistical analysis showed a significant effect of genotype, age and 
their interaction on the levels of testosterone, while the levels of 17 B 
estradiol were significant only for the interaction between genotype 
and age (Table 4). 
 
 
Table 4: Effects of age, genotype and their interaction were analyzed by a 
two-way ANOVA test: * p <0.05, ** p <0.01, *** p <0.001. 
 
Figure 4 showed the levels of androgen metabolites in sciatic nerve 
of SREBP-1c KO mice and WT animals at 2 and 10 months of age. 
Bonferroni post-test showed that T levels were signiﬁcantly higher at 2 
months of age in sciatic nerve of SREBP-1c KO in comparison to WT 
animals. The same effect was observed on the levels of 17β-E (Fig.4). 
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Fig.4: The levels of DHEA, T and its metabolites in sciatic nerve of wild type 
(WT, blue bars) and sterol regulatory-binding protein-1c (SREBP-1c) knock-
out (KO, red bars) mice at 2 and 10 months of age. Data (n = 5 for each 
experimental group) are expressed as pg/mg tissue ± SEM. Bonferroni post-
test: *p < 0.05; **p < 0.01, and ***p < 0.001 versus WT (see histogram). 
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4.3.2 NEUROACTIVE STEROID LEVELS IN PLASMA 
 
As reported in table 5, Anova analysis has revealed a signiﬁcant 
effect of genotype only on PREG (p < 0.05).  
 
 
Table 5: Effects of age, genotype and their interaction on the levels of some 
neuroactive steroid levels in plasma of SREBP-1c KO and WT animals. The 
effects were analyzed by a two-way ANOVA test: * p <0.05, ** p <0.01, *** 
p <0.001. 
 
Figure 5 showed the levels of crucial metabolites in plasma of SREBP-
1c KO mice and WT animals at 2 and 10 months of age. Quantitative 
analysis has indicated at 2 months of age, no significant difference in 
the levels of PREG and PROG and 17β-E, while Testosterone 
concentration was signiﬁcantly higher in plasma of SREBP-1c KO 
compared with wild type group. At 10 months of age no significant 
difference was observed between WT and SREBP-1c KO groups for all 
the other neuroactive steroids (Fig.5). 
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Fig.5: The levels of DHEA, T and its derivatives in plasma of wild type (WT) 
and sterol regulatory-binding protein-1c (SREBP-1c) knock-out (KO) mice at 
2 and 10 months of age. Data (n = 5 for each experimental group) are 
expressed as pg/µL plasma T SEM. Bonferroni post-test: *p < 0.05; **p < 0.01, 
and ***p < 0.001 versus WT (see histogram). UDL: Under detection limit. 
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4.3.3 GENE EXPRESSION OF ENZYME IN STEROIDOGENESIS 
 
The gene expression profile of crucial steroidogenic enzymes in 
sciatic nerve of Srebf-1cKO and control mice were detected at 2 and 
10 months of the age.  
Anova analyses showed significantly effect of the age on the levels 
of all enzymes analyzed. In addition, analyses have indicated an 
effect of genotype and age on the levels of 5α-R but no effect 
concerning the interaction between two parameters. To concern 3α-
HSOR, a significant effect of genotype, age and interaction was 
observed.in the case of the enzyme P450scc, two way analysis has 
also revealed a significant interaction between two two parameters 
(table 6). 
 
Table 6: Effects of age, genotype and their interaction on gene expression 
levels in sciatic nerve of SREBP-1c KO and WT animals. The effects were 
analyzed by a two-way ANOVA test: * p <0.05, ** p <0.01, *** p <0.001 
 
Figure 7 shows the levels of the enzymes in sciatic nerve of Srebf-1cKO 
and wild type mice in the described experimental conditions. At two 
months of age, only P450scc enzyme shows a significant increase of 
the gene expression in Srebf-1cKO with respect to WT. In contrast, at 
10 months of age, a significant increase in gene expression of the 
enzymes 5α-R and 3α-HSD enzymes were detected in SREBP-1c KO 
while no difference was observed in the gene expression of the 
enzyme P450scc (Fig.7). 
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Fig.7: Levels of P450scc, 5α-R, 3α-HSD enzymes in the sciatic nerve of WT 
and SREBP-1c KO mice, respectively at 2 and 10 months of age. The data 
are expressed as relative mRNa ± SEM. Statistical analysis is performed using 
the Bonferroni test: * p <0.05, ** p <0.01, *** p <0.001 vs WT. 
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4.4 DISCUSSION 
 
As described before, recently it has been demonstrated that the lack 
of SREBP-1c, the key lipogenic transcription factor lead to 
development peripheral neuropathy (Cermenati et., 2015). Several 
studies have observed changes in the levels of neuroactive steroids 
in sciatic nerve in different disease such as aging process, physical 
injury, diabetes (Melcangi et al., 2016; Giatti et al., 2015). According 
to previous paper, we found that SREBP-1c KO mice show alteration 
in the levels of some neuroactive steroids in sciatic nerve. Specifically, 
as reported in the figure 3. altered levels of PREG are observed 
depend on the evolution of the pathology. Indeed, at 2 months of 
age, we observed that SREBP-1c KO mice showed signiﬁcantly higher 
levels of this neuroactive steroid in comparison to what was reported 
in WT animals, while at 10 months of age, lower levels of PREG was 
detected. According to this results, gene expression of the enzyme 
converting cholesterol into PREG followed this pattern, at least at 2 
months of age. Specifically, P450scc enzyme shows a significant 
increase of the gene expression in Srebf-1cKO with respect to WT 
(Figure 7). This finding together the observation that PREG levels did 
not change in plasma, suggest a specific effect of SREBP-1c on 
steroidogenesis in the peripheral nerve. Changes in the levels of PREG 
induces, as reported in the figure 3, alterations in the levels of other 
metabolites of neurosteroidogenesis. Specifically, the levels of PROG 
are significantly decreased at 2 and 10 months of age in SREBP-1c 
KO mice when compared with WT animals. Concerning other 
metabolites of progestin pathway, the pattern depends on the age 
of the mice.  
The levels of 5α-DHP significantly decreased at 2 months of age in 
sciatic nerve of SREBP-1c KO mice in comparison with control 
animals; in opposite, at 10 months of age, an increased in the levels 
53 
 
 
of 3α,5α-THP, metabolite of 5α-DHP, was observed when compared 
with WT animals. The increase of 3α,5α-THP levels is in agreement with 
the high gene expression of the enzyme 3 a-HSD, which convert DHP 
in 3α,5α-THP (Figure 7).  In addition, also the levels of other metabolite 
of 5α-DHP, 3β,5α-THP were significantly modified in opposite mode at 
2 and 10 months, namely decreased and increased respectively. 
With respect to androgens pathway, at 2 months of age only 
testosterone levels were significantly higher in sciatic nerve of SREBP-
1c KO mice than in WT animals. This modification is not a peculiarity 
of sciatic nerve, but is present also in plasma. In addition, the levels 
of a metabolite of T, 17β-E, are also signiﬁcantly higher in sciatic nerve 
of SREBP-1c KO mice than in WT animals but no variation in plasma 
levels is observed. Taken together, these results could be interpreted 
as an endogenous response to the ﬁrst signs of peripheral 
neuropathy. These data are in agreement with what observed in 
other papers. Indeed, Patte-Mensah et al. have demonstrated that 
neuropathic pain (i.e., an important component of peripheral 
neuropathy) has an important impact on neurosteroidogenesis with 
a transient up-regulation of the PREG levels (Patte-Mensah et al. 
2014). The high levels of neuroactive steroids as a response to the ﬁrst 
stage of the peripheral neuropathy might be interpreted like a 
mechanism for coping with neurodegeneration. For instance, PREG 
has been reported to counteract the decrease of the amounts of 
myelin membranes induced by cryolesion in sciatic nerve as well as 
to increase, in guided regeneration of the rabbit facial nerve, the 
number and g-ratio of myelinated nerve (Koenig et al. 1995). At 10 
months, when the peripheral neuropathy was evident, we found low 
levels of PREG and PROG and high levels of 3α,5α-THP and 3β,5α-THP. 
SREBP-1c KO sciatic nerve at 10 months of age experience energy 
depletion and mitochondrial dysfunction from a metabolic point of 
view. (Cermenati et al. 2015). To this regard, it well known that 
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Schwann cells and neurons rely on glycolysis as fuel source. The lack 
of SREBP-1c imposes cells to use fatty acid instead of glucose and 
lactate leading mitochondrial dysfunction in sciatic nerve of SREBP-
1c null mice.  On this basis, it might be possible that at 2 months of 
age, at the onset of the peripheral neuropathy, mitochondria try to 
counteract the first stage of neurodegeneration by inducing P450scc 
expression and consequently the levels of its product PREG.  
On the other hand, at 10 months of age, the peripheral nerve boots 
the mitochondria to cope energy depletion, the levels of PREG are 
decreased as result of altered mitochondrial function. To 
compensate this altered mitochondrial function, SREBP-1c KO sciatic 
nerve increased both 5α-R and 3α-HSOR expression levels and 
relative metabolites. Several papers have, indeed, demonstrated 
that also PROG derivatives are effective in protecting peripheral 
nerve by aging damage, physical injury ((Melcangi et al. 2000;) and 
diabetic peripheral neuropathy (Cermenati et al. 2012; Mitro et al. 
2014). 
In conclusion, this research has highlighted one of application of LC-
MS/MS; specifically, this study has indicated the ability of method to 
identify and quantify simultaneous main neuroactive steroids 
involved in steroidogenesis. These findings suggest that during the 
development of peripheral neuropathy because of the blunted FA 
biosynthesis (Cermenati et al., 2015), at the 2 months of age, the PNS 
try to counteract the early stages of neurodegeneration modulating 
the neuroactive steroids synthesis. During the progression of the 
pathology, the peripheral nerve boosts mitochondria to cope energy 
depletion due to the reduced glycolysis, and the levels of 
mitochondria-produced hormone such as PREG are decreased and 
downstream neuroactive steroids are instead increased. To 
summarize, these experiments have demonstrated that impair 
lipogenesis due to lack of SREBP-1c induces alteration on 
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steroidogenesis altering different levels of neuroactive steroids. These 
data further support the idea that neuroactive steroids, by a cross-
talk with FA biosynthetic pathway, may represent a possible 
therapeutic strategy for peripheral neuropathy.  
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5.1 INTRODUCTION 
 
Diabetes mellitus is a metabolic disease where improper glycemic 
control may induce several complications in different organs.  
This pathological situation can be the result of the lack or reduced 
insulin secretion from pancreas or an improper insulin function on 
target tissues such as liver, skeletal muscle, adipose tissues and others; 
a phenomenon known as insulin resistance (American Diabetes 
Association, 2009). The type 1 diabetes mellitus or insulin dependent 
diabetes mellitus, IDDM, is usually diagnosed in children and young 
adults, as a result of an autoimmune destruction of the insulin 
producing beta cells in the pancreas. Type 1 diabetes accounts for 
5–10% of all diabetic patients around the world.  
Another type of diabetes, non-insulin dependent diabetes mellitus 
(NIDDM) or type 2 diabetes, represents the most common form of 
diabetes (85–90% of all cases of diabetes). An important 
complication of diabetes mellitus is represented by the damage in 
the PNS (i.e., diabetic peripheral neuropathy) and CNS (i.e., 
diabetic encephalopathy). 
Diabetic peripheral neuropathy occurs in more than 50% of all 
diabetic patients (Zochodne, 2007) involving a spectrum of 
functional and structural changes in peripheral nerves. These 
include slowing in nerve conduction velocity (NCV) followed by 
axonal degeneration, paranodal demyelination and loss of 
myelinated ﬁbers (Sugimoto et al., 2000).   
In addition, as shown in an experimental model of type 1 diabetes 
(i.e., rats raised diabetic by injection with streptozotocin, STZ), 
peripheral nerve alterations are represented by myelin invaginations 
in the axoplasm (infoldings) and myelin evaginations in the Schwann 
cell cytoplasm (outfoldings) as well as alterations in myelin 
compaction such as abnormally wide incisures and abnormal 
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separation of myelin lamellae (Veiga et al. 2006). Important myelin 
components, such as proteins (i.e., myelin protein zero, P0, and 
peripheral myelin protein 22, PMP22) and lipids (i.e., phospholipids, 
fatty acids, and cholesterol content), are also strongly affected by 
diabetes mellitus (Cermenati et al., 2012). 
In addition, in a mouse model of type 1 diabetes, prolonged 
hyperglycemia leads to accumulation of small fragmented 
mitochondria in DRG probably as a consequence of altered 
mitochondrial dynamics, such as fission and fusion and/ or trafficking 
(Vincent et al. 2010). In addition, neuropathological events, including 
diabetic encephalopathy (i.e., damage induced by diabetes in the 
brain) and diabetic peripheral neuropathy (i.e., damage in the 
peripheral nervous system), affect neuroactive steroid levels.  
Indeed, it has been observed decreased levels of several 
neuroactive steroids in plasma of streptozotocin (STZ) induced 
diabetes mice at three months (M. Pesaresi, et al., 2010). 
In addition, long-term type 1 diabetes has been shown to alter 
cholesterol homeostasis not only in the peripheral nervous system but 
also in cerebral cortex (Cermenati et al., 2017). Furthermore, STZ 
diabetes in rats also aﬀect mitochondrial function in the cerebral 
cortex (Mastrocola, et al., 2005).  
In the last years, a growing experimental evidence suggests that 
cholesterol oxidation products, known as oxysterols, play an 
important role in the development of major chronic diseases, 
including atherosclerosis, alzheimer's disease, and inflammatory 
bowel disease (Testa G et al., 2018). In addition, several studies have 
indicated that oxysterol may be the link between altered cholesterol 
metabolism and human diseases (Testa et al., 2018). Oxysterols are 
involved in various key steps of these complex processes. They are 
signaling molecules and interact with different types of protein 
targets exhibiting regulatory function on cholesterol metabolism and 
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homeostasis (Javitt NB, 2002). Oxysterols, also, act as ligands to 
nuclear receptors; indeed, as reported in Theofilopoulos et al (2012), 
activation of LXR by oxysterols can induce neurogenesis of 
dopaminergic neurons.  
On the basis of previous data and taking into account that functional 
and biochemical changes may already occur in short-term diabetes 
(Suzuki, et al., 2010), in this study by means of LC-MS/MS tecnique, 
levels of cholesterol, oxysterols and neuroactive steroids in the 
cerebral cortex after one month of diabetes, were evaluated. 
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5.2 MATERIALS AND METHODS 
 
All solvents and reagents were liquid chromatography–mass 
spectrometry (LC-MS) grade (CARLO ERBA Reagents, Milano, Italy). 
PREG, PROG, 5-DHP, 3,5-THP, 3β,5-THP, T, 5V-DHT, 3- diol, 3 β -
diol, dehydroepiandrosterone (DHEA), 17 β -E and the  internal 
standards 17b-Estradiol- 2,3,4-13C3, PREG-20,21-13C2 , and PROG-2,3,4-
13C3 such as  cholesterol and cholesterol-2,2,3,4,4,6-d6 its internal 
standard were purchased from Sigma-Aldrich, Milan, Italy.  
 (S.I) 7α-hydroxycholesterol, 7β-hydroxycholesterol were bought from 
Steraloids (Newport, RI, USA), 24(S)-hydroxycholesterol, 27-
hydroxycholesterol, 7-ketocholesterol were obtained from 
ResearchPlus (Barnegat, NJ, USA). 
 
5.2.1 ANIMALS  
 
Male Sprague-Dawley rats (175–200 g at arrival, Charles River 
Laboratories, Lecco, Italy) were housed in the animal care facility of 
the Dept of farmacological and biomolecular sciences (DiSFeB). All 
animals were kept in standard rat cages with food and tap water 
available ad libitum and under controlled temperature (21 ± 4 ° C), 
humidity (40–60%), room ventilation (12.5 air changes for h) and light 
cycles (12 - hour light / dark cycle; on 7 am / oﬀ 7 pm). 
The animals were randomly divided into two experimental groups: 1) 
control non-diabetic rats (CTRL) and 2) diabetic rats (STZ) following 
institutional guidelines (D.L. No. 26, March 4, 2014, G.U. No. 61 March 
14, 2014) and international laws and policies (EEC Council Directive 
2010/63, September 22, 2010: Guide for the Care and Use of 
Laboratory Animals, United States National Research Council, 2011). 
Diabetes was induced by a single injection of freshly prepared STZ (60 
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mg/kg body weight; Sigma-Aldrich, Milano, Italy) in citrate buﬀer 
(0.09 M pH 4.8). (Pesaresi et al.,2010). After 48 h only animals with 
glucose level above 300 mg/dl were considered as diabetic. After 
one month, CTRL and STZ rats were sacriﬁced, the cerebral cortex 
and plasma were collected, weighed and stored at−80 °C until 
analysis. 
 
5.2.2 NEUROACTIVE STEROIDS ANALYSIS 
 
Neuroactive steroids (table 2) levels have been evaluated by liquid 
chromatography tandem mass spectrometry (LC-MS/MS) in plasma 
and cerebral cortex at one months of age in non-diabetic and STZ 
animals, after extraction and puriﬁcation as described in the chapter 
4.2.2. 
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5.2.3 CHOLESTEROL AND OXYSTEROLS ANALYSIS 
 
The levels of free and total cholesterol as well as of its mainly 
metabolites, reported in the table were assessed by LC–MS/MS in the 
cerebral cortex of non-diabetic and STZ rats.  
 
Analytes Parent ions Transitions 
detected 
CID 
Cholesterol d6 375.5 135,149,161, 
243, 257 
35 
Cholesterol (CHOL), 369.5 135, 161, 175, 
233, 243 
35 
27-
hydroxycholesterol 
(27-OH) 
385.5 135, 147, 161, 
175, 189, 203, 
215, 229, 243, 
257 
35 
7α-
hydroxycholesterol 
(7α-OH) 
385.5 145, 149, 173, 
187, 201, 213, 
219, 227, 241, 
255 
35 
7β-
hydroxycholesterol 
(7β- OH) 
385.5 145, 149, 173, 
187, 201, 213, 
219, 227, 241, 
255, 
35 
7-ketocholesterol 
(7-keto) 
401.0 365, 383  35 
24(S)-
hydroxycholesterol 
(24(S)-OH) 
385.5 135, 147, 161, 
175, 189, 203, 
215, 229, 243, 
257 
35 
Table 7: parent ion, transition detected and collision energy of the 
cholesterol and oxysterols under evaluation   
 
Cerebral cortex of CTRL and STZ rats (60mg), were weighted, added 
with internal standards and homogenized in 1 ml of MeOH/ACN (1:1, 
v/v) using the TissueLyser (Qiagen, Italy). After centrifugation at 12,000 
rpm for 5 min, supernatant was divided in two aliquots: one for the 
analysis of free cholesterol and oxysterols and the other for total 
cholesterol. To analyze total cholesterol levels, aliquots were added 
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in chloroform-MeOH 1:1, v/v and 1M HCl:MeOH (1:1, v/v). The  mixture 
was shaken for 2 hours with mechanical agitator at room 
temperature. After addition of a volume of chloroform-water (1:1, 
v/v), the lower organic phase was collected, transferred into new 
tubes and dried under nitrogen flow (Taguchi et al. 2010). 
Quantitative analysis was performed using calibration curves 
prepared and analyzed in the same day of the biological samples 
ranging 0.5ng-5ng/sample and and 10-100µg/sample for oxysterols 
and cholesterol respectively. 
The analyses were performed using a linear Ion Trap Mass 
Spectrometer equipped with an atmospheric pressure chemical 
ionization (APCI) source (LTQ, ThermoElectron Co., San Jose, CA, USA,  
a Surveyor liquid chromatography (LC) Pump Plus and a Surveyor 
Autosampler Plus (ThermoElectron Co.). The mass spectrometer was 
operated in positive-ion mode and in tandem mode (MS⁄MS) using 
helium as collision gas. 
The LC mobile phases were: ACN/MeOH/H20 (76:20:4) (phase A) and 
Isopropanol (phase B). The gradient (flow rate 1 ml/min) was as 
reported in the following table: 
 
 
 
 
 
 
 
Table 8: Elution gradient of the chromatographic analysis 
An Intersil ODS column C18 (150 x 3 mm, 3 µm; GL sciences) was used 
for chromatographic separation and maintained at 40°C.  
 
Time A% B% 
0.0 100 0 
15.0 100 0 
15.5 50 50 
35.0 50 50 
35.5 100 0 
50.0 100 0 
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5.2.4 QUANTITATIVE REAL TIME PCR (RT-QPCR) 
 
Gene expression analysis was performed extracting mRNAs from 
cerebral cortex of control and diabetic rats. The extraction was 
performed using DirectzolTM miniprep kit (Zymo Research, Irvine, 
California, USA) following specific manucfaturing protocol. The gene 
expression of enzyme was carried out with TaqMan quantitative real-
time PCR using a CFX96 real-time system (Bio-Rad Lab, Segrate, Italy). 
The relative quantification of the genes was carried out by 
comparing their quantity with that of 36B4 and setting up a standard 
curve.  The gene expression analyses were performed for: 
 
Sterol regulatory element-binding protein 2 (SREBP2): enzyme 
involved in the regulation of the biosynthesis of cholesterol.  
3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMG-CoA R): 
rate-controlling enzyme of the mevalonate pathway 
Low density lipoprotein receptor (LDLR): internalizes cholesterol-rich 
lipoproteins into the cellular compartment.  
Steroidogenic acute regulatory protein (StAR,): enzyme involved in the 
transport of cholesterol in the mitochondria. 
Translocator protein- 18 kDa (TSPO,): enzyme involved in the transport of 
cholesterol in the mitochondria. 
P450 side chain cleavage (P450scc): enzyme responsible for the 
conversion of cholesterol to pregnenolone. 
Sterol 27-hydroxylase (Cyp27A1): a gene encoding a cytochrome P450 
oxidase. 
Sterol O-acyltransferase (SOAT1): enzyme that favors the conversion of 
free cholesterol into cholesteryl esters. 
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Hormone sensitive lipase (HSL): enzyme that hydrolyzes cholesteryl esters 
into free cholesterol 
apolipoprotein E (APOE): protein involved in the metabolism of fats in the 
body 
ATP- binding cassette G1 (ABCG1) and ATP- binding cassette A1 
(ABCA1): enzyme involved in cholesterol efflux 
 
5.2.5 STATISTICAL ANALYSIS 
 
Student’s t-test was used to compare results obtained by the analysis 
of plasma and cerebral cortex of CTRL and STZ rats. A p-value < 0.05 
was considered signiﬁcant. All statistical analyses were per- formed 
with GraphPad PRISM version 6 (San Diego, CA, USA). 
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5.3 RESULTS 
 
5.3.1 SHORT-TERM DIABETES ALTERED NEUROACTIVE STEROID LEVELS 
IN THE CEREBRAL CORTEX AND PLASMA. 
 
The levels of different neuroactive steroid were evaluated in cerebral 
cortex and plasma of control non-diabetic and diabetic rats by LC–
MS/MS.  
Specifically, in the figure 8 the levels of progestin neuroactive steroids 
in cerebral cortex are reported. As shown, we found that the levels 
of PREG, PROG and 3α,5α-THP significantly decreased in diabetic 
animal when compared with non-diabetic group (Fig.8).  
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Fig.8: The levels PREG and its derivatives in cerebral cortex of control (CTRL) 
and diabetic rats (STZ) at 1month of age. Data (n = 5 for each experimental 
group) are expressed as pg/mg tissue ± SEM; t-Student: *p < 0.05; **p < 0.01, 
and ***p < 0.001 versus CTRL. UDL: Under detection limit. 
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To concern androgen pathway, neuroactive steroids analysis has 
indicated significant difference in some neuroactive steroids. We 
found that the levels of T and two metabolites such as 5α-DHT and 
3α-diol, were significantly decreased in the cerebral cortex after 
short- term diabetes when compared with control group (Fig.9). 
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Fig.9: The levels DHEA and its derivatives in cerebral cortex of control (CTRL) 
and diabetic rats (STZ) at 1month of age. Data (n = 5 for each experimental 
group) are expressed as pg/mg tissue ± SEM; t student: *p < 0.05; **p < 0.01, 
and ***p < 0.001 versus CTRL. UDL: Under detection limit. 
 
 
 
  
68 
 
 
Neuroactive steroid levels were, also, evaluated in plasma of STZ and 
control animals at one month of age. The levels of neuroactive 
steroids were assessed by LC-MS/MS. As reported in the figure 10, a 
significant decrease in the levels of metabolites 3b,5a-THP were 
observed. 
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Fig.10: The levels PREG and its derivatives in plasma of control (CTRL) and 
diabetic animals (STZ) at 1month of age. Data (n = 5 for each experimental 
group) are expressed as pg/µL plasma ± SEM; t-sudent: *p < 0.05; **p < 0.01, 
and ***p < 0.001 versus CTRL. UDL : Under detection limit. 
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Fig.11: The levels DHEA and it derivatives in plasma of control (CTRL) and 
diabetic animals at a1month of age. Data (n = 5 for each experimental 
group) are expressed as pg/µL plasma ± SEM; t student: *p < 0.05; **p < 0.01, 
and ***p < 0.001 versus CTRL. UDL : Under detection limit (<0.05 pg/µL) 
 
In the figure 11, analysis of androgens is reported. Analysis showed a 
significant decrease in the levels of Testosterone (**p < 0.01) and its 
metabolite 3a-DIOL ((**p < 0.01) were observed in STZ group.  
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5.3.2 SHORT-TERM DIABETES ALTERED THE LEVELS OF CHOLESTEROL 
AND OXYSTEROLS IN THE CEREBRAL CORTEX 
 
The levels of free cholesterol and oxysterols as well as total cholesterol 
were evaluated in cerebral cortex in both experimental groups.  
The analyzes were carried out by LC-MS/MS and the 
chromatographic profile obtained is shown in the following figure:  
 
 
Fig.12: Chromatogram of cholesterol and its derivates.  
 
Quantitative analysis was performed on the basis of calibration 
curves prepared daily. The figure shows a calibration curve obtained 
for cholesterol analysis:  
 
Fig.13: calibration curve of cholesterol 
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Figure 14 shows free and total cholesterol levels in STZ and control  rats at 
one month of age. As reported, the levels of free cholesterol in the 
cerebral cortex was significantly decreased by short-term diabetes, while 
no difference in the levels of total cholesterol was observed.  
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Fig.14: The levels of free and total cholesterol in STZ (red bar) and control 
(blue bar)  at 1month of age. Data (n = 5 for each experimental group) are 
expressed as µg/mg ± SEM; t student: **p < 0.01versus CTRL.  
 
As reported in fig. 15, the levels of 24(S)-hydroxycholesterol (24(S)-OH) 
and 27-hydroxycholesterol (27-OH), two enzymatic metabolites of 
cholesterol, were significantly decreased in the cerebral cortex of 
diabetic animals. In opposite, the levels of 7α-hydroxycholesterol (7α-
OH), 7β-hydroxycholesterol (7β- OH) and 7-ketocholesterol (7-keto), 
three non-enzymatic oxysterols, were significantly increased in 
diabetic animals when compared with control group. 
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Fig.15: The levels of free oxysterols in diabetic and control rats at a1month 
of age. Data (n = 5 for each experimental group) are expressed as ng/mg 
± SEM; t student: **p < 0.01, ***p < 0.001versus versus CTRL.  
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5.3.3 GENE EXPRESSION OF ENZYME INVOLVED IN BIOSYNTHESIS OF 
CHOLESTEROL AND STEROIDOGENESIS 
 
To support alteration in the levels of cholesterol derivates and 
neuroactive steroids, the gene expression profile of enzymes involved 
in the biosynthesis of cholesterol and in metabolism of neuroactive 
steroids were evaluated (see chapter 5.2.4) The analyses were 
performed in cerebral cortex of diabetic and control animals at 1 
month of age.  
In the figure 16 (panel A) the gene expression of enzymes involved in 
cholesterol biosynthesis was reported. Results indicated that gene 
expression levels of sterol regulatory element-binding protein 2 
(SREBP2), which is involved in the regulation of the biosynthesis of 
cholesterol, significantly decreased in STZ group when compared 
with control rats.  In addition, the gene expression of HMG-CoA R (3-
hydroxy-3-methyl-glutaryl-coenzyme A reductase) and LDLR (low 
density lipoprotein receptor) were down regulated in the cerebral 
cortex of diabetic rats. The first one is the rate-controlling enzyme of 
the mevalonate pathway, , while LDLR internalizes cholesterol-rich 
lipoproteins into the cellular compartment. 
In the figure 16 (panel B) the expression levels of mitochondrial 
cholesterol carriers such as Steroidogenic acute regulatory protein 
(StAR) and Translocator protein- 18 kDa (TSPO). According to the low 
levels of PREG observed in cerebral cortex of STZ animals, also gene 
expression of Star and TSPO decreased significantly while the 
expression of P450scc, the first neurosteroidogenic enzyme that 
convert cholesterol in PREG, remained unchanged. In addition, 
according to the decrease in the levels of 27 OH observed in the 
cerebral cortex of diabetic animals, a downregulation of Cyp27A1 
was observed in STZ rats.  
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Fig.16: A) the gene expression of enzyme involved in cholesterol 
biosynthesis in the cerebral cortex of diabetic and control animals. B) the 
mRNA levels of molecules correlated to mitochondrial metabolism of 
cholesterol in the cerebral cortex of both experimental groups. C) One 
month after the STZ induction, diabetes modiﬁes mRNA levels of molecules 
involved in cholesterol bioavailability in the rat cerebral cortex. Data (n = 
10 animals for each experimental group) are expressed as mean ± SEM; t 
student: **p < 0.05**p < 0.01   p < 0.001 versus CTRL. 
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To evaluate bioavailability of cholesterol, the expression levels of 
sterol O-acyltransferase (SOAT1), which favors the conversion of free 
cholesterol into cholesteryl esters, and hormone sensitive lipase (HSL), 
which hydrolyzes cholesteryl esters into free cholesterol were 
assessed in both experimental groups. As showed in figure 16c SOAT1 
mRNA remained unchanged in the cerebral cortex, while, HSL mRNA 
levels were down-regulated by short-term diabetes. 
In addition, efflux another important pathway in the regulation of 
cholesterol homeostasis. We have observed an increase in 
apolipoprotein E (APOE) gene expression in the cerebral cortex of STZ 
rats. Finally, the eﬀect of diabetes on two transporters highly 
expressed in the CNS and involved in cholesterol efflux like the ATP- 
binding cassette G1 and A1 (i.e., ABCG1 and ABCA1) were 
detected. As reported in figure 16c, mRNA levels of ABCG1 and 
ABCA1 were increased in the cerebral cortex after short-term 
diabetes confirming that diabetes aﬀects cholesterol efflux. 
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5.4 DISCUSSION 
 
The results have indicated that neuroactive steroid levels are 
changed in the cerebral cortex after one month after the induction 
of diabetes. Specifically, significantly decreased levels of 
neuroactive steroids such as PREG, PROG, THP, T, DHT and 3α-diol 
were observed in diabetic rats when compared with control animals 
(Figure 8 and 9). 
In addition, it has been observed that short-term diabetes doesn't 
affect PREG plasma levels, suggest a specific effect of short-term 
diabetes on neurosteroidogenesis (Figure 10 and 11.  
Furthermore, because cholesterol is precursor of steroidogenesis and 
it has been observed that diabetes affects the free cholesterol 
content of the brain (Cermenati et al, 2017), changes in the levels of 
PREG could be due to the availability of cholesterol.  
On the basis of this considerations, we want to confirm that the level 
of free cholesterol, evaluated by LC-MS/MS, was significantly 
decreased in the cerebral cortex of STZ rats in comparison with 
control animals (Figure 14). 
Previous papers have demonstrated that two months after the 
induction of diabetes, the biosynthesis of cholesterol decreased, 
probably due to the decrease in the levels of cholesterols, accordling 
with this evidence, the gene expression of SREBP2, HMG-COA R and 
LDLR was reduced in the cerebral cortex of STZ rats suggesting that 
decreased cholesterol synthesis may be involved in the lower levels 
of free cholesterol (Figure 16A). In addition, we reported that the 
gene expression of HSL, enzymes that plays a key role in the 
regulation of intracellular free cholesterol amount and in 
steroidogenesis, was decreased in the cerebral cortex of diabetic 
rats, suggesting that also this mechanism may contribute to the 
reduced amount of free cholesterol. Furthermore, to support the 
77 
 
 
results observed by LC-MS/MS analyses after one month after the 
injection of STZ, an upregulation of APOE gene expression and a 
downregulation of LDLR were observed in the cerebral cortex, 
suggesting an increase of cholesterol efflux from cellular 
compartment without an efficient uptake. These data is in 
agreement with previous study reporting an increase in APOE 
immunoreactivity in the hippocampus STZ mice short term diabetes 
(Revsin et al., 2005). In addition, the increase in the mRNA levels of 
APOE in the cerebral cortex of STZ rat was correlated with an increase 
of ABCG1 and ABCA1 gene expression, (Karten et al., 2006).  
Cholesterol homeostasis also includes active metabolism into 
different oxysterols, like 24(S)-OH and 27-OH cholesterol. LC-MS/MS 
analyses have indicated that short- term diabetes significantly 
reduced levels of these oxysterols (24(S)-OH and 27-OH cholesterol) 
in the cerebral cortex (Figure 15). According to these evidences, a 
decrease in mRNA levels of the enzyme Cyp27A1, which catalizes 27-
OH cholesterol synthesis at the inner mitochondrial membrane, was 
observed (Figure 16B). Moreover, a signiﬁcant increase of the 
oxysterol levels (i.e., 7α-OH, 7β-OH and 7-keto) was detected (Figure 
15). These molecules may have a crucial role in the down-regulation 
of HMG-CoA R. Indeed, as demonstrated in cultures of rat astrocytes, 
the treatment with 7β-OH or 7-keto inhibits the activity of HMG- CoA 
R (Behr et al.,1991). 
The data, here reported, highlights that the decrease in PREG levels 
detected in the cerebral cortex of diabetic rats could be due to a 
decrease in cholesterol bioavailability. Indeed, mRNA levels of HMG-
CoA R and HSL were down-regulated while those formed by 
oxidative activity (7β-OH and 7-keto) were upregulated in the 
cerebral cortex of STZ rats. In addition, the gene expression of SOAT1 
(i.e., the enzyme producing cholesteryl esters) remained unmodiﬁed. 
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These ﬁndings suggest that short-term diabetes has speciﬁc effects 
depending on the brain region considered. This consideration is in 
agreement with what observed in the hippocampus, where free 
cholesterol levels were increased while 27-OH was unmodiﬁed (S. 
Romano et al., 2017).  
Regarding the LC-MS / MS analysis on neuroactive steroids, the 
decrease in PREG concentration observed in the cerebral cortex of 
STZ rats may be due to an impairment of steroidogenic machinery. 
Indeed, short-term diabetes causes a decrease in StAR and TSPO 
mRNA levels.  
The observed reduction of StAR gene expression, associated with the 
decrease of TSPO gene expression, is in agreement with previous 
observations in previous paper as well as in cerebral area, as in the 
hippocampus (Kraemer et al.,2004; Romano et al.,2017). In contrast 
to observation conducted in hippocampus (Romano et al.,2017), in 
the cerebral cortex the gene expression of P450scc (i.e., the enzyme 
that converts cholesterol into PREG) was not altered. It is important to 
highlight that mitochondrial P450scc uses electrons from NADPH via 
the ferredoxin (FDX) and ferredoxin reductase (FNR) (Wada et al., 
1999). Furthermore, P450scc and CYP27A1 in adipocytes can 
compete for the common redox partners, because CYP27A1 binds 
with higher affinity to FDX than P450scc (Miller et al., 2011) Therefore, 
since Cyp27A1 gene expression and the levels of 27-OH, which 
promotes metabolism of cholesterol to more polar compounds that 
are more efﬁciently exported from cells than the parent compound, 
were diminished in the cerebral cortex of STZ rats, a functional shift of 
cholesterol metabolism into the mitochondrial compartment to 
maintain sufficient amount of PREG could be hypothesized. 
The present study has highlighted as LC-MS/MS technique, using a 
linear ion trap mass spectrometer, allow simultaneous quantification 
of 13 neuroactive steroids in a single analysis. In addition, 6 cholesterol 
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derivatives by LC-MS/MS analyses in cerebral cortex and plasma of 
short-term diabetes and control animal were detected. As reported 
in different papers, alterations in the levels of neuroactive steroids 
could be considered as important functional diagnostic markers for 
diabetic encephalopathy (Lavaque, et al., 2004: Melcangi et al., 
2014). In addition, treatments with neuroactive steroids or with 
inducers of steroidogenesis are effective in reducing neural damage 
in STZ experimental models (Cermenati et al., 2017; Pesaresi et al., 
2010). Indeed, diabetic encephalopathy is characterized by 
neurophysiological and structural changes and this complication 
may increase the risk of cognitive deﬁcits and dementia especially in 
type-1 diabetic patients (Gispen et al., 2000) On this point of view, 
the ﬁnding that type 1 diabetes seems to affect neurosteroidogenesis 
before than peripheral steroidogenesis suggests that a therapeutic 
approach based on these molecules against diabetic 
encephalopathy could be more appropriate and effective in the 
early stages of the pathology. 
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6. Lipidomic studies in a mice model 
of SCA38, a newly identified form of 
spinocerebellar ataxia. 
Manuscript in progress 
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6.1 INTRODUCTION 
 
Spinocerebellar Ataxias (SCAs) are a group of autosomal dominant 
neurological disorders. SCAs are phenotypically characterized by 
gait and limb ataxia, incoordination of eye movements and speech 
and hand disturbances. Cerebellar hypometabolism is well 
documented and considered a main diagnostic marker (Durr, 2010). 
Ataxia is defined as a disturbance of balance and incoordination 
occurring in the absence of muscle weakness and can arise from 
dysfunction of the cerebellum (Fogel et al., 2006). The cerebellum 
plays a critical role in this process through the integration of 
multimodal sensory data with motor output predictions to yield 
smooth well-timed movement (Manto, et al., 2012).  
The cerebellar syndrome is often associated with other neurological 
signs such as pyramidal or extrapyramidal signs, ophthalmoplegia, 
and cognitive impairment (Harding, 1983). Onset is usually during the 
third or fourth decade of life, but it can occur in childhood or old age 
(Harding, 1983). Atrophy of the cerebellum and brainstem are most 
often the prominent features, but other structures can be affected, 
leading to a substantial range of phenotypes (Yamada et al., 2008). 
Recently it has been identified a new form of Spinocerebellar Ataxia 
type 38 (SCA38) caused by mutations in the ELOVL fatty acid 
elongase 5 gene (Di Gregorio et al., 2014). SCA38 is a rare form of 
inherited ataxia and the disease onset is in the fourth decade of life, 
characterized by slowly progressive gait ataxia and associated in 
most of the cases with pes cavus and hyposmia. The disease 
progresses with limb ataxia, dysarthria, dysphagia, ophthalmoparesis, 
and, in the later stages, sensory loss. Brain imaging documented 
cerebellar hypometabolism with sparing of cerebral cortex (Borroni 
et al., 2016). 
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ELOVL5 encodes an elongase enzyme involved in the synthesis of 
long-chain polyunsaturated fatty acids (lc-PUFA) and is highly 
expressed in murine and in human Purkinje cells (Di Gregorio et al., 
2014). They are inhibitory neurons that regulate the complex and 
coordinated movements, preventing an abrupt movement. In 
humans, Purkinje cells can be damaged by a variety of causes: toxic 
exposure, for example alcohol or lithium; autoimmune diseases; 
genetic mutations that cause spinal-cerebellar ataxias (Marmolino et 
al., 2010). 
Polyunsaturated fatty acids are required for the normal development 
of the central nervous system, indeed in recent years, 
polyunsaturated fatty acids like DHA have gained much attention 
due to promising results in a number of neurodegenerative conditions 
such as Parkinson disease (Hacioglu et al., 2012; Yassine et al., 2017). 
In this contest, several studies have demonstrated that oral intake 
DHA reduces brain pathology improving cognitive deficits and 
protecting against synaptic degeneration (Lim et al 2005; Green et 
al 2007). Given the specific expression of ELOVL5 in Purkinje cells, a 
reduction in the fatty acid synthesis could damage cerebellar 
function. PLs containing ω-3 PUFAs seem to show beneficial effects in 
different disorders through specific mechanisms and a plethora of 
bioactivities including their ability to modulate the eicosanoid 
pathway (Burri et al., 2012; Hishikawa et al., 2017; Murray et al., 2015). 
On this premisess, the aim of the study was to better understand the 
pathophysiological mechanisms underlying this new human SCA38. 
ELOVL5 KO mouse model was generate in collaboration with the 
Department of Medical Sciences and of Neurosciences (University of 
Turin). To characterize the phenotype features, behavioral tests were 
performed by University of Turin at three different ages in order to 
track the progressive development of the disease.  
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To investigate lipidomic pattern we have evaluated fatty acids 
profile and phospholipids family. The analysis was conducted in 
Purkinje cells and in several tissues (plasma, cerebellum, sciatic nerve 
and olfactory bulb) obtained from mouse (control and KO mice 
model) at 15 months of age. The analysis of the metabolic profile and 
of specific metabolites in biological samples provide an insight into 
the metabolic state and the biochemical processes of the organism 
and, therefore, may indicate the onset and the stage of the disease. 
Lipidomic profile analyses was carried out by means liquid 
chromatography tandem mass spectrometry (LC-MS/MS). 
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6.2 MATERIAL AND METHODS 
 
6.2.1 ANIMALS AND REAGENTS 
 
All animal experimental procedures have been approved by the 
Ethical Committee of the University of Torino and authorized by the 
Italian Ministry of Health (authorization number: 161/2016-PR). ELOVL5 
knockout (KO) mice have been kindly provided by Dr. Moon and Dr. 
Horton of the UT Southwestern Medical Center (Moon et al.,2009) and 
bred in Animal Facility at NICO (Univesity of Turin).  
ELOVL5KO and wild type mice were used for all the experimental 
paradigms, while heterozygous mice were only used as breeders. 
Both ELOVL5KO mice and their wild type littermates were kept on 
natural diet without animal derivatives, containing essential PUFAs 
like linoleic and α-linolenic acids, but excluding the presence of 
omega-3 and omega-6 PUFAs downstream Elovl5, such as DHA, EPA 
and AA. The Lipidomic analyses was carried out on purkinje cells 
isolated by cerebellar cortex and in different tissues at 15 months of 
age: plasma, cerebellum, sciatic nerve and olfactory bulb. The 
lipidomic analysis was performed at 15 months because at this age, 
Motor Deficits and Cerebellar Atrophy in ELOVL5 Knock Out Mice was 
observed (Hoxha et al., 2017). 
 
REAGENTS AND STANDARDS 
 
Fatty acids standards were purchased from Sigma Aldrich. All 
Phospholipids standards were purchased from Avantpolar Lipids. All 
solvents used were purchased from Sigma Aldrich with mass 
spectrometry grade.  
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6.2.2 LIPIDOMIC ANALYSIS 
 
The levels of total fatty acids and phospholipids were evaluated by 
means of Liquid Chromatography-tandem mass spectrometry (LC-
MS/MS) according to Cermenati et al. (2012). Briefly, internal 
standards (13C-labeled linoleic acid and 13C-labeled palmitic acid) 
were added to samples (50µL for plasma and 10 mg for tissues), and 
lipid extraction was performed using 1 mL of methanol 
(MeOH)/Acetonitrile (1/1; v;v). After centrifugation at 12,000 rpm for 
5 minutes, the supernatant was divided in two aliquots:  
 A: phospholipid analysis; 
 B: total fatty acid profile; 
 
PHOSPHOLIPIDS ANALYSIS 
 
ESI analysis of the major phospholipid classes (table 8) was 
accomplished by utilization of either positive or negative ionization 
modes. The identity of the different phospholipid families was 
confirmed using pure standards, namely one for each family 
comparing the acquired mass spectra. Methanolic extracts were 
analyzed by a 5 minutes run in both positive and negative ion mode 
with a 268 multiples reaction monitoring (MRM) transition in positive 
mode and 88 MRM transition in negative mode. A specific transition 
or specific neutral loss was used for each phospholipid family (see 
table 9). To establish the correct transition, infusions of a standard for 
each family was carried out to optimize all parameters 
An API 4000 triple quadrupole instrument (AB Sciex, USA) equipped 
with ESI source was used. The mobile phase was 0.1% formic acid in 
MeOH for positive analysis using a Synergie Hydro RP column and 5 
mM ammonium acetate pH 7 in MeOH for negative analysis using a 
Luna CN column.  
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MultiQuantTM software version was used for data analysis and peak 
review of chromatograms. Changes between detected 
phospholipid families were calculated as percent of single 
phospholipid species normalized to total phospholipid analyzed. 
 
PHOSPHOLIPIDS FAMILY Q1 Q3 DP CE 
LYSO-PHOSPHATIDILCHOLINE 
(LYSO-PC) 
454.6 184 95 30 
PHOSPHATIDILCHOLINE (PC) 636.7 184 95 30 
LYSO-
PHOSPHATIDYLETHANOLAMINE 
(LYSO-PE) 
596.4 133 95 30 
PHOSPHATIDYLETHANOLAMINE(PE) 596.4 133 95 30 
PLASMALOGENS (PC ae+ PE ae) 636.7 184 95 30 
SPHINGOMYELIN (SM) 647.8 184 95 30 
PHOSPHATIDYLSERINE (PS) 639.4 186 95 30 
PHOSPHATIDYLINOSITOL (PI) 712.4 241 115 51 
PHOSPHATIDYLGLYCEROL (PG) 624.4 153 115 51 
LYSO-PHOSPHATIDIC ACID (LYSO-
PA) 
550.4 153 115 51 
PHOSPHATIDIC ACID (PA) 550.4 153 115 51 
CERAMIDES (CER) 793.5 97 115 51 
SULFATIDES (SUL) 482.7 264 95 30 
Table 9: Parent ion (Q1) and fragment ion (Q3) of internal standards for 
each phospholipids family, potential difference (DP) and collision energy 
(CE) obtained after single infusion. 
 
FATTY ACID ANALYSIS 
 
Total FAs were obtained from samples by acid hydrolysis (Taguchi, R 
et al. 2010). Fraction B was resuspended in chloroform-MeOH 1:1, v/v. 
1M HCl:MeOH (1:1, v/v) was added to the total lipid extract and 
shaken for 2 h. A mixture of chloroform:water (1:1, v/v) was added 
and the lower organic phase was collected, divided in two aliquots 
and dried under nitrogen flow. The residue was resuspended in 1 ml 
of MeOH and 10µL injected for LC-MS/MS analysis. 
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Quantitative analysis was performed on the basis of calibration 
curves prepared and analyzed daily  
The mobile phases were: water/10 mM isopropylethylamine/15 mM 
acetic acid (phase A) and MeOH (phase B). The gradient (flow rate 
0.5 ml/min) was as follows:  
 
 
 
 
 
 
 
 
Table 10: Elution gradient of the chromatographic analysis 
 
The Hypersil GOLD C8 column (100 mm × 3 mm, 3 μm) was 
maintained at 40°C. The mass spectrometer was operated in 
selective ion monitoring (SIM/SIM) mode. Peaks area were evaluated 
using a Dell workstation by means of the software Analyst release 4.1. 
The mass spectrometer was operated in negative-ion mode. 
 
 
 
 
 
 
 
 
 
 
Time 
(min) 
A% B% 
0.00 20 80 
20.00 1 99 
25.00 1 99 
25.10 20 80 
30.00 20 80 
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Fatty acid Q1 Q3 DP CE 
PALMITIC ACID 
(C16:0) 
255 255 -50 -10 
PALMITOLEIC ACID 
(C16:1) 
253 253 -50 -10 
MARGARIC ACID 
(C17:0) 
269 269 -50 -10 
STEARIC ACID 
(C18:0) 
283 283 -50 -10 
OLEIC ACID (C18:1) 281 281 -50 -10 
LINOLEIC ACID 
(C18:2) 
279 279 -50 -10 
γ-LINOLENIC ACID 
(C18:3) 
277 277 -50 -10 
ARACHIC ACID ( 
C20:0) 
311 311 -50 -10 
ARACHIDONIC ACID 
(C20:4) 
303 303 -50 -10 
EPA (C20:5) 301 301 -50 -10 
BEHENIC ACID 
(C22:0) 
339 339 -50 -10 
ERUCIC ACID 
(C22:1) 
337 337 -50 -10 
DHA (C22:6) 327 327 -50 -10 
NERVONIC ACID 
(C24:1) 
365 365 -50 -10 
IS Linoleic 13C18 297 297 -50 -10 
Table 11: parent ion (Q1), fragment ion (Q3), potential difference (DP) 
and collision energy (CE) of fatty acids under evaluation  
 
QUANTITATIVE PROTEIN BCA 
 
The pellets obtained after extraction were resuspended in RIPA 1X, lysed 
using tissue lyser (Qiagen, Milan, Italy) and centrifuged for 3 minutes.  5 μL 
of supernatant were transferred to the plate, diluted 1: 1 with water and 
added with 190 μL of BCA Bicinchoninic Protein Assay Kit (Euroclone). The 
samples were incubated for 30 minutes at 37 ° C and their absorbance 
was then evaluated using an Envision® MultilabelPlate Reader (Perkin 
Elmer) spectrophotometer, set at 570 nm. To quantify proteins a 
calibration curve was prepared at a known concentration of BSA (range 
0.0-1.0 mg / mL. 
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6.2.3 STATISTICAL ANALYSIS  
 
Data from female and male mice were pooled together because 
they did not show significant difference.  
Comparisons between two experimental groups (Elovl 5 KO and WT) 
were done with unpaired two tailed Student’s t-test or by two way or 
one way analyses of variance (ANOVA), followed by Holm-Sidak post 
hoc correction to concern motor test. 
Unpaired Student’s t-test was performed for lipidomic analysis and all 
statistical analyses were performed using GraphPad PRISM version 6. 
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6.3 RESULTS 
 
6.3.1 LIPIDOMIC PROFILE IN PURKINJE CELLS OF ELOVL5KO MICE 
MODEL AND of WILD TYPE.  
 
TOTAL FATTY ACID PROFILE IN PURKINJE CELLS OF ELOVL5KO MICE MODEL 
AND of WILD TYPE.  
 
Total fatty acids were evaluated in both experimental groups out by LC-
MS/MS and the chromatographic profile obtained is shown in the 
following figure: 
 
 
Fig.17: Chromatografic separation of fatty acids under evaluation. 
 
Quantitative analysis was performed using calibration curves 
prepared daily. The figure shows a calibration curve obtained for 
Linoleic acid. 
 
Fig.18: calibration curve of Linoleic acid. 
y = 1,3761x - 0,0179
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To study the specific function of ELOVL5 in Purkinje cells, in 
collaboration with the Department of Medical Sciences and 
Neurosciences of the University of Turin, we compared the levels of 
the total fatty acid in Purkinje cells isolated from ELOVL5KO mice and 
from control animals.  
Total fatty acid profile, as shown in figure 19, are mainly unchanged 
except a decrease for both Arachidonic Acid and 
Docosahexaenoic Acid that does not reach the statistic significance. 
It is important to underline that two fatty acids are the metabolites 
product by the action of the ELOVL5 enzyme in FAs biosynthesis.  
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Fig.19: Total fatty acid levels in purkinje cells isolated from ELOVL5 KO (red 
bars) and wild type mice (blue bars). Data are expressed as ng/ug 
proteins (mean± SEM). 
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PHOSPHOLIPIDS ANALYSIS IN PURKINJE CELLS OF ELOVL5KO MICE MODEL 
AND of WILD TYPE.  
 
Phospholipids were evaluated in Purkinje cells isolated from 
cerebellar cortex of ELOVL5 KO mice and wild type animals. 
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            B 
 
Fig.20: Effect of ELOVL5 mutation on phospholipids family in Purkinje cell. A) 
Volcano plot reported all different phospholipids families detected. B) bar 
graph denoting fold change (in log2 base) of the statistically different levels 
of phospholipids between the experimental groups (n=6 for group). Data 
are expressed as mean± SEM.).  p values for two groups were determined 
by Unpaired Student’s t-test. * p< 0.05 vs Wild type. 
 
Volcano plot (Figure 20A) in which are reported all phospholipids 
species evaluated expressed as log2 Fold change, highlighted that 
only two phospholipids show significant differences in ELOVL5 KO 
group when compared with control group. These two phospholipids 
belongs to phosphatidylcholines (PCs) family and 
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phosphatidylethanolamines (PEs) family. In particular, PCaa 36:5, PC 
carrying different fatty acids bound to the glycerol by two ester 
linkages at sn-1 and sn-2 position (di-acyl form), significantly 
increased in ELOVL5 KO group while PEaa42:10 significantly 
decreased in ELOVL5 KO animals in comparison with wild type group 
(Fig 20B).  
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6.3.2 LIPIDOMIC PROFILE IN PLASMA OF ELOVL5KO MICE MODEL AND 
WILD TYPE.  
 
TOTAL FATTY ACID PROFILE IN PLASMA OF ELOVL5KO MICE MODEL AND 
WILD TYPE.  
 
Total fatty acids levels in plasma of ELOVL5 KO mice model and wild 
type at 15 months of age was reported in figure 21. A significant 
decrease in Arachidonic Acid (AA, 20:4, ω6), Eicosapentaenoic Acid 
(EPA, 20:5, ω3) and Docosahexaenoic Acid (DHA, 22:6, ω3) levels in 
ELOVL5 KO group when compared with wild type is evident.  
This result is in agreement with trend observed in serum of patients 
affected by SCA38 (Di Gregorio et al., 2014).  
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Fig.21: Total fatty acid levels in plasma of ELOVL5 KO and wild type group. 
Data are expressed as ng/µl (mean± SEM; n=6 each group); p values were 
determined by Unpaired Student’s t-test. * p< 0.05 vs Wild type.  
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PHOSPHOLIPIDS ANALYSIS PROFILE IN PLASMA OF ELOVL5KO MICE MODEL 
AND WILD TYPE.  
 
As shown (Fig.22B), the % composition in terms of phospholipids 
species detected in the two different experimental groups was 
comparable. However, Volcano plot (Fig.22A), in which are reported 
all phospholipids evaluated, highlighted that 61 phospholipids show 
significant difference in plasma of ELOVL5KO and wild type. Detailed 
analysis indicates that mutation of ELOVL5KO, induces significantly 
changed in many phospholipids of different species. As shown in 
Figure 22C, significant difference in five different lyso-
phosphatidylcholines (LysoPCs), fourteen phosphatidylcholines (PCs) 
carrying different fatty acids bound to the glycerol by two ester 
linkages at sn-1 and sn-2 position (di-acyl form, PCaa) are 
detectable. PCs with less of 38 carbon atoms significantly increased 
in ELOV5 KO mice while PCs with more of 38 carbon atoms 
significantly decreased in ELOVL5 KO mice in comparison with wild 
type group. In addition, difference in fifteen 
phosphatidylethanolamines (PEs) are also evident. PEs carrying less 
than 38 carbon atoms in fatty acid composition displayed an 
increase in contrast PEs with a long chain fatty acid composition (> 
38 total carbon) showed a significant decrease in ELOVL5KO with 
respect to control group (Fig.22D). We have, also, detected 
plasmalogens components, which are lipids characterized by the 
presence of a vinyl ether linkage at the sn-1 position and ester linkage 
at the sn-2 position of the glycerol (alkyl-acyl form, ae). The most 
common plasmalogens are ethanolamine 
(plasmenylethanolamines, PEae) or choline (plasmenylcholines, 
PCae). 
In plasma analysis seventeen plasmalongens showed significantly 
changes: fifteen PCae and two PEae (Figure 22C and 22D). Similarly, 
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to what observed in PCs and PEs, also plasmalogens with less of 38 
carbon atoms showed a significative increase in ELOVL5 KO when 
compared with control mice. Plasmalogens with more of 38 carbon 
atoms highlighted a significative decrease in ELOVL5 KO group in 
comparison with wild type group. 
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Fig.22: effect of ELOVL5 mutation in plasma (PL) phospholipids family. A) 
Volcano plot reported all different phospholipids families detected. B) 
composition of phospholipid species observed in PL of two experimental 
groups (% of total PLs).  C) bar graph denoting fold change (in log2 base, 
red bar) of the statistically different levels of Lyso-PC and PC between the 
experimental groups (n=6 for group). D) bar graph denoting fold change 
(in log2 base, red bar) of the statistically different levels of PE between the 
experimental groups (n=6 for group. E) bar graph denoting fold change (in 
log2 base, red bar of SM, PG PI and Sulfatides between the experimental 
groups (n=6 for group). Data are expressed as mean± SEM.).  p values by 
Unpaired Student’s t-test. * p< 0.05, **<0.01, ***<0.001 vs Wild type.  
 
We have, also, observed that seven sphingomyelin (SM) showed 
significative difference between two experimental groups, namely, 
four significantly increase and three significantly decrease (Figure 
22E) In addition, one phosphatidylglycerol (PG) significantly 
increased in ELOVL5 KO mice when compared with wild type group 
while one sulfatides (SUL) and one phosphatidylinositol (PI) showed a 
significant decrease in ELOVL5 KO mice in comparison with control 
animals (Figure 22E). 
Plasma phospholipids with less than 38 total carbons showed an 
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increase in ELOVL5KO, while in all species, phospholipids with a long 
chain fatty acid composition (> 38 total carbon) a significant 
decrease in ELOVL5KO mice in comparison with control mice is 
observed.   
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6.3.3 LIPIDOMIC PROFILE IN CEREBELLUM OF ELOVL5KO MICE MODEL AND 
WILD TYPE.  
 
TOTAL FATTY ACID PROFILE IN CEREBELLUM OF ELOVL5KO MICE MODEL 
AND WILD TYPE.  
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Fig.23: Total fatty acid levels in cerebellum of ELOVL5KO and wild type (n=6) 
group. Data are expressed as ng/mg tissue (mean± SEM). 
 
In figure 23 are reported the levels of total fatty acids also in 
cerebellum of two experimental groups (ELOVL5KO and WT). 
Quantitative analysis does not show any significative difference in 
ELOVL5KO when compared with wild type.  
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PHOSPHOLIPIDS ANALYSIS IN CEREBELLUM OF ELOVL5KO MICE MODEL 
AND WILD TYPE.  
 
Different species of phospholipids are evaluated in cerebellum of 
ELOVL5KO and WT groups. As shown (Figure24B), the % composition 
in terms of phospholipids species detected in the two different 
experimental groups in cerebellum was comparable. However, 
Volcano plot (Figure 24A), in which are reported all phospholipids 
evaluated, highlighted that phospholipids show significant difference 
in cerebellum of ELOVL5KO in comparison with wild type.  
 
    A       B 
      
Fig.24: effect of ELOVL5 mutation on cerebellum (CRB) phospholipids 
family. A) Volcano plot reported all different phospholipids families 
detected. B) composition of phospholipid species observed in CRB of two 
experimental group (% of total PLs).  
 
Therefore, a detailed analysis of each family and statistically 
difference between species are reported (Fig.25). Specifically, as 
shown in figure 25A, a significant difference in eleven different PCs 
carrying different fatty acids bound to the glycerol by two ester 
linkages at sn-1 and sn-2 position (di-acyl form, PC aa) were 
detected. PCs carrying less of 38 carbon atoms in fatty acid 
composition displayed an increase in cerebellum of ELOVL5KO in 
comparison with that of control mice, while PCs carrying > 38 total 
carbon atoms showed a significant decrease in ELOVL5KO when 
compared with wild type group.  
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Among PEs analyzed, species with less of 38 carbon atoms in the di-
acyl form (PEaa) showed an increase statistically significative in 
ELOVL5KO group when compared with wild type group. In opposite, 
three PEs carrying more of 38 carbon atoms in fatty acid composition 
displayed a decrease in ELOVL5KO mice in comparison with control 
mice (Figure 25B). In addition, twelve plasmalogens showed 
significant difference; specifically, two PCae and five PEae with less 
of 38 carbon atoms show an increase in ELOVL5KO mice when 
compared with wild type animals (Figure 25A and 25B).  
Furthermore, five plasmalogens (four PCae and one PEae) with more 
than 38 carbon atoms significantly decrease in cerebellum of 
ELOVL5KO with respect to control group (Figure 25A and 25B). 
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Fig. 25: bar graph denoting fold change (in log2 base) of the statistically 
different levels of phospholipids between the experimental group (n=6 for 
group). A) bar graph of statistically different levels of PC in cerebellum of 
ELOVL5KO (red bar) in comparison with WT (blue bar). B) bar graph 
statistically different levels of PE in cerebellum of ELOVL5KO (red bar) in 
comparison with WT (blue bar). C) bar graph statistically different levels of 
SM, Cer, PG and PA in cerebellum of ELOVL5KO (red bar) in comparison 
with WT (blue bar). Data are expressed as mean± SEM.).  p values for two 
groups were determined by Unpaired Student’s t-test. * p< 0.05, **<0.01, 
***<0.001 vs Wild type. 
 
Finally, four SM have highlighted a significative decrease in 
ELOVL5KO group while one ceramide (CER) and three phosphatidic 
acid (PA) showed a significant increase in ELOVL5KO in comparison 
with WT group (Figure 25C). Furthermore, two phosphatidylglycerols 
(PG) showed statistically significative changes between two groups. 
(Figure 25C). 
Similarly, to that observed in plasma, even in cerebellum analysis, we 
found that phospholipids of different species showed a trend 
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depending of total carbon number of fatty acids. Phospholipids 
carrying less of 38 carbon atoms in fatty acid composition displayed 
an increase in ELOVL5KO mice in comparison with control mice.  
In opposite, PLs with a long chain fatty acid composition (> 38 total 
carbon atoms) showed a significant decrease in ELOVL5KO group 
when compared with wild type group.  
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6.3.4 LIPIDOMIC PROFILE IN SCIATIC NERVE OF ELOVL5KO MICE MODEL 
AND WILD TYPE.  
 
TOTAL FATTY ACID PROFILE IN SCIATIC NERVE OF ELOVL5KO MICE MODEL 
AND WILD TYPE. 
 
Total fatty acids analysis is performed in sciatic nerve (SN) of ELOVl5 
KO mice model compared with wild type animal. As shown in Figure 
26, total fatty acids level in SN is unchanged in the two experimental 
groups.  
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Fig.26: Total fatty acid levels in sciatic nerve (SN) of ELOVL5KO and wild type 
group. Data are expressed as ng/mg tissues (mean± SEM; n=6 each group 
 
105 
 
 
PHOSPHOLIPIDS ANALYSIS PROFILE IN SCIATIC NERVE OF ELOVL5KO MICE 
MODEL AND WILD TYPE. 
 
Phospholipids analysis in sciatic nerve have indicated that the most 
abundant lipids present in sciatic nerve are PCs, PEs and 
plasmalogens. As shown in figure 27B, the % composition in terms of 
phospholipids species detected in the two different experimental 
groups was comparable. Volcano plot (Fig.27A), in which are 
reported all phospholipids evaluated, highlighted that phospholipids 
show significant difference in sciatic nerve of ELOVL5KO in 
comparison with wild type.  
        A                                                              B  
 
Fig.27: effect of ELOVL5 mutation on sciatic nerve (SN) phospholipids family. 
A) Volcano plot reported all different phospholipids families detected. B) 
composition of phospholipid species observed in SN of two experimental 
groups (% of total PLs).  
 
Moreover, a detailed analysis of significative difference for each 
family is reported in figure 28. Specifically, as shown in figure 28A, a 
significant difference in two Lyso-PC and seven PCs with different 
fatty acids composition to the glycerol in the di-acyl form (aa) were 
obsrved. Three PCs with less of 38 total carbon atoms significantly 
increased in ELOVL5KO group in comparison with control group, 
while four PCs carrying more 38 carbon atoms in fatty acids 
composition showed a decrease in ELOVL5KO mice with respect to 
control mice. Furthermore, we found that thirteen PEs were 
significantly different in ELOVL5KO group with respect to control. 
Among these, five of them highlighted a decrease while eight 
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showed an increase in ELOVL5KO mice when compared with control 
group (Figure 28B). Similarly, to what observed with PCs, PEs carrying 
less than 38 carbon atoms in the fatty acid composition showed an 
increase in ELOVL5KO group in comparison with wild type. In 
opposite, PLs with more than 38 carbon atoms in composition of FAs 
has showed a significant decrease in ELOVL5KO mice. PLs analysis in 
sciatic nerve highlighted that eleven plasmalogens (seven PCae and 
four PEae) are statistically different between two groups. 
Plasmalogens with less of 38 total carbon atoms show an increase in 
ELOVL5KO mice when compared with wild type animals, while 
plasmalogens carrying long-chain polyunsaturated fatty acids 
composition (>38 carbon atoms) showed a significant decrease in in 
sciatic nerve of ELOVL5KO with respect to control group (Figure 28A, 
28B). 
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Fig. 28: bar graph denoting fold change (in log2 base) of the statistically 
different levels of phospholipids in sciatic nerve between the experimental 
group (n=6 for group). A) bar graph of statistically different levels of PC in 
sciatic nerve of ELOVL5KO (red bar) in comparison with WT (blue bar). B) 
bar graph statistically different levels of PE in sciatic nerve of ELOVL5KO (red 
bar) in comparison with WT (blue bar). C) bar graph statistically different 
levels of SM, Cer, Sul, PG, PA and PI in sciatic nerve of ELOVL5KO (red bar) 
in comparison with WT (blue bar). Data are expressed as mean± SEM.).  p 
values for two groups were determined by Unpaired Student’s t-test. * p< 
0.05, **<0.01, ***<0.001 vs Wild type. 
 
Finally, other phospholipids (SM, CER, PG, PA, PI, SUL) showed a 
significant increase in ELOVL5KO mice when compared with wild 
type animals (Figure 28C).  
Analysis of phospholipids in sciatic nerve of ELOVL5KO and wild type 
mice highlighted that PLs with less than 38 carbon atoms in the fatty 
acid composition were significantly increased in ELOVL5KO group in 
comparison with wild type. PLs with more than 38 carbon atoms in 
composition of FAs has showed a significant decrease in ELOVL5KO 
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mice.  
6.3.5 LIPIDOMIC PROFILE IN OLFACTORY BULB OF ELOVL5KO MICE 
MODEL AND WILD TYPE.  
 
TOTAL FATTY ACIDS PROFILE IN OLFACTORY BULB OF ELOVL5KO MICE 
MODEL  
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Fig.29: Total fatty acid levels in sciatic nerve of ELOVL5KO and wild type 
(n=6) group. Data are expressed as mean± SEM. p values for two groups 
were determined by Unpaired Student’s t-test. * p< 0.05 vs Wild type 
 
The analysis of total fatty acids is performed in olfactory bulb of 
ELOVL5KO animal compared with control mice at 15 months of age. 
In contrast with what observed in cerebellum and sciatic nerve, 
analysis highlighted some statistically difference between the two 
experimental groups. Specifically, as shown in figure 29, we have 
observed that the levels of palmitic acid (16:0), γ-linolenic acid (18:3) 
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and EPA (20:5) are significantly increased in ELOVL5KO mice in 
comparison with control animals.  
 
PHOSPHOLIPIDS ANALYSIS IN OLFACTORY BULB OF ELOVL5KO MICE 
MODEL AND WILD TYPE 
 
Analysis of different phospholipids family species in Olfactory Bulb 
(OB) indicated alterations in them composition. As shown in figure 
30B, the % composition in terms of phospholipids species detected in 
the two different experimental groups was different for some species. 
To confirm this data, quantitative analysis showed significantly 
changes in the total amount of ELOVL5KO mice in comparison with 
control animal for the follow PLs family: Lyso-PC, PCs, PEs, 
plasmalogens, SM and PS (Figure 30C). 
Volcano plot (Figure 30A), in which are reported all phospholipids 
evaluated showed that many phospholipids display differences in 
olfactory bulb of ELOVL5KO when compared with wild type.  
A detailed analysis of each family and statistically difference 
between species are reported in figure 30. 
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Fig.30: effect of ELOVL5 mutation on olfactory bulb (OB) phospholipids 
family. A) Volcano plot reported all different phospholipids families 
detected. B) composition of phospholipid species observed in OB of two 
experimental groups (% of total PLs). C) Total amount of different PLs families 
detected. Data are expressed as mean± SEM.).  p values for two groups 
were determined by Unpaired Student’s t-test. * p< 0.05, **<0.01, ***<0.001 
vs Wild type. 
 
Specifically, Figure 31A shows statistically significant difference in PCs 
carrying different fatty acids bound to the glycerol by two ester 
linkages at sn-1 and sn-2 position (di-acyl form, PCaa) and 
plasmanylcholines (PCae) with a vinyl ether linkage at the sn-1 
position and ester linkage at the sn-2 position of the glycerol (alkyl-
acyl form, ae). PCaa and PCae carrying less of 38 carbon atoms in 
fatty acid composition displayed an increase in ELOVL5KO mice in 
comparison with control mice, while PLs with a long chain fatty acid 
composition (>38 total carbon atoms) showed a significant decrease 
in Elovl5KO group when compared with wild type group (figure 31A). 
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In figure 31B, statistically significant differences of PEs carrying 
different fatty acids bound to the glycerol by two ester linkages at sn-
1 and sn-2 position (di-acyl form) and plasmenylethanolamines, 
(PEae) with a vinyl ether linkage at the sn-1 position and ester linkage 
at the sn-2 position of the glycerol (alkyl-acyl form, ae) are reported. 
Specifically, we found that PEaa and PEae carrying less of 38 carbon 
atoms in fatty acid composition highlighted an increase in ELOVL5KO 
mice in comparison with group mice, while phospholipids with a long 
chain fatty acid composition (> 38 total carbon atoms) showed a 
significant decrease in ELOVL5KO group when compared with wild 
type group. 
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Fig.31: effect of ELOVL5 mutation in olfactory bulb (OB) of different species 
altered. A) bar graph denoting fold change (in log2 base) of the statistically 
different levels of PCs between the experimental groups (n=6 for group). B) 
bar graph denoting fold change (in log2 base) of the statistically different 
levels of PEs between the experimental groups (n=6 for group). C) bar graph 
denoting fold change (in log2 base) of the statistically different levels of SM, 
PI, ceramides and PS between the experimental groups (n=6 for group). 
Data are expressed as mean± SEM.). p values for two groups were 
determined by Unpaired Student’s t-test. * p< 0.05, **<0.01, ***<0.001 vs Wild 
type. 
 
Finally, in figure 31C are reported other PLs that showed statistically 
significant difference in ELOVL5KO group when compared with wild 
type animals. Specifically, we found that SM, LacCer, Gcer, PS 
highlighted an increase in ELOVL5KO mice in comparison with WT 
group ans two phospholipids belong to phosphatidylinositolo (PI) 
family showed a decrease in ELOVL5KO group when compared with 
wild type animals. These two PLs are PI carrying 36 carbon atoms and 
1 double bound and PI carrying 40 carbon atoms and 4 double 
bound. 
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6.3.6 PHOSPHOLIPIDS CHANGING IN DIFFERENT TISSUES 
 
Phospholipids analysis highlighted alterations of different species in all 
tissues considered. As reported in figure 32, Olfactory Bulb analysis 
showed more changes (green) in different species of PLs compared 
to other tissue.  
 
 
Fig.32: Diagram showing the phospholipids change in plasma (red), 
cerebellum (yellow), sciatic nerve (blue) and olfactory bulb (green).  
 
In addition, figure 32 shows that in all tissue in all tissues considered, 
10 PLs significantly changed in ELOVL5KO group in comparison with 
control animals. A significant decrease in the PC aa C:40:4 and PE 
aa C:40:4 were detected (Figure 33). 
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Fig.33: bar graph denoting fold change (in log2 base) of the statistically 
different levels of common phospholipids in all tissues considered between 
the experimental group (n=6 for group). Data are expressed as mean± 
SEM.). p values for two group comparisons were determined by Unpaired 
Student’s t-test.  PLASMA: * p< 0.05, **<0.01, ***<0.001 vs Wild type. CRB # 
<0.05, ##<0.01, ###<0.001 vs WT. SN § <0.05, §§<0.01, §§§<0.001 vs WT. OB 
£ <0.05, ££<0.01, £££<0.001 vs WT  
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6.4 DISCUSSION 
 
Spinocerebellar Ataxia 38 (SCA38) is a new rare form of Ataxia 
caused by single missense mutations in the Very Long Chain Fatty 
Acid Elongase 5 Gene, (ELOVL5) described for the first time by Di 
Gregorio  Di Gregorio et al., 2014). The ELOVL5 protein belongs to a 
family of enzymes localized in the endoplasmic reticulum involved in 
elongation of very long-chain (>16 C) fatty acids, are. The main 
clinical findings in this disease are ataxia, hyposmia and cerebellar 
atrophy. Mice in which ELOVL5 has been knocked out represent a 
model of the loss of function of SCA38. In agreement with this aspect 
mice with a complete deletion of ELOVL5 are generated. These 
animal show the main symptoms observed in SCA38 patients, motor 
deficits at the beam balance test and hyposmia (Di Gregorio et al., 
2014; Borroni et al., 2016, Hoxha et al., 2017).  
Hoxha et al. (2017) described as ELOVL5KO mice displayed a marked 
deficit in the beam balance test. On the contrary, the rotarod test 
did not reveal any significant difference between two experimental 
groups. A phenotype similar to that of ELOVL5KO mice was described 
by Larivière et al.(2015) in a murine model of autosomal recessive 
spastic ataxia of Charlevoix-Saguenay. They were able to detect the 
first signs of ataxia with the balance beam test but not with the 
rotarod test. On the other hand, other researchers have found an 
impaired performance of SCA3 mice in the rotarod test despite the 
absence of deficits in the balance beam test (Switonski et al., 2015). 
These different data suggest that the motor tests might have a 
different sensitivity in revealing motor impairment, depending on the 
severity of ataxia and of the peculiar features of each ataxic 
syndrome.  
The motor impairment observed in ELOVL5KO mice is reminiscent of 
the initial stages of ataxia, especially in slowly progressing forms 
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observed in spinocerebellar ataxia (SCA) patients, in which instability 
can be revealed by tandem gait while regular walking is not affected 
(Bodranghien et al., 2016). 
ELOVL5 encodes an elongase enzyme involved in the synthesis of 
long-chain polyunsaturated fatty acids (lc-PUFA) and is highly 
expressed in murine and human Purkinje cells (Di Gregorio et al., 
2014). They are inhibitory neurons that regulate the complex and 
coordinated movements, preventing an abrupt movement. In 
humans, Purkinje cells can be damaged by a variety of causes: toxic 
exposure, for example alcohol or lithium; autoimmune diseases; 
genetic mutations that cause spinal-cerebellar ataxias. Given the 
specific expression of ELOVL5 in Purkinje cells a reduction in the fatty 
acid synthesis could damage cerebellar function. 
Lipidomic studies in this mice model were performed to characterize 
the phenotype. These studies have revealed alterations in total fatty 
acid composition and particularly phospholipids of different species 
have changed in ELOVL5KO animal when compared with wild type 
group. Lipidomic analysis in purkinje cells isolated from ELOVL5KO 
animal has indicated alterations in the FAs synthesis; we have found 
a trend to decrease in the main metabolites product by the action 
of ELOVL5 enzyme such as AA 20:4 and DHA 22:6. Different species of 
phospholipids founding significantly different in ELOVL5KO group 
when compared with wild type. Particularly, we have found that 
phosphatidylethanolamine with long chain polyunsaturated fatty 
acid composition (PE aa 42:10) significantly decreased in ELOVL5KO 
animal; these phospholipids could have in its FAs composition DHA 
and AA. These founding suggest that mutations within elovl5 gene 
induces an alteration in the synthesis of long chain-polyunsaturated 
fatty acids in ELOVL5 knockout mice.  
Total fatty acids profile and phospholipids were evaluated in in 
plasma, cerebellum, sciatic nerve and olfactory bulb ELOVL5KO and 
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wild type mice at 15 months of age, where animals display Motor 
Deficits and Cerebellar Atrophy (Hoxha et al., 2017).  
Total fatty acids analysis in cerebellum and sciatic nerve didn’t show 
any difference between two experimental groups. we do not 
observe the same pattern obtained in cells because the 
characterization of the fenotype was carried out in cerebellum (due 
to its involvement in hyposmia) and not in cerebellar cortex, which 
Purkinje cells are mainly located. 
In plasma is evident the same trend observed in serum analysis of 
SCA38 patients (Di Gregorio et al.,2014) Specifically, Arachidonic 
Acid (AA, 20:4, ω6), Eicosapentaenoic Acid (EPA, 20:5, ω3) and 
Docosahexaenoic Acid (DHA, 22:6, ω3) levels were significantly 
decreased in ELOVL5KO group with respect to wild type group. Data 
obtained from plasma analysis could suggest alterations in FAs 
synthesis in liver, where mainly produced.  
Phospholipids analysis have indicated many changes in ELOVL5KO 
mice levels when compared with wild type group in all tissues 
considered. Specifically, we have observed two trends depending 
from fatty acids composition for cerebellum and sciatic nerve and 
olfactory bulb analysis. PLs with a total of 38 carbon atoms 
significantly decreased in ELOVL5KO group in comparison with wild 
type group; in contrast, phospholipids carrying long-chain 
polyunsaturated fatty acids composition (>38 carbon atoms) showed 
a significant decrease in the levels in ELOVL5KO group with the 
respect to control.  
Lipid metabolism plays an important role in the development and 
normal functionality of the CNS, given that this organ has the highest 
lipid content after adipose tissue. Altered levels of lipid molecules, 
such as fatty acids, are demonstrated in the neuronal system of 
individuals affected by neurodegenerative diseases, mental 
disorders, stroke, and trauma (Adibhatla et al., 2007). 
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A variety of neurological diseases, particularly hereditary spastic 
paraplegias (Tesson, C et al.,2012; Boukhris, A et al.,2012; Martin, E et 
al.,2013) and related diseases (Morgan, N.V et al.,2006) also have 
altered lipid metabolism in human cells, which confirms the 
importance of lipid homeostasis in brain membranes.  
Data obtained in this study, have indicated alterations in lipids 
pattern; In particularly these results have highlighted as PLs 
composition is affected in ELOV5KO mice model, suggesting that PLs 
could have an important role in molecular mechanism underlying 
SCA38 considering their ability to modulate the eicosanoid pathway 
(Burri et al 2012; Hishikawa et al 2017; Murray et al 2015).  
Olfactory Bulb analysis showed more changes in different species of 
PLs compared to other tissue suggesting probably a cross talk 
between alteration in lipidomic pattern with hyposmia observed in 
patients (Borroni et al.,2016) and in olfactory test performed in mice 
model (Hoxha et al.,2017). 
However, different phospholipids showed significantly changes in all 
of tissues considered between two experimental groups.  
In all tissues considered, 10 PLs significantly changed in ELOV5KO 
group in comparison with control animals. A significant decrease in 
the PC aa C:40:4 and PE aa C:40:4 were detected; these two 
phospholipids probably contain arachidonic acid (20:4) and arachic 
acid (20:0) confirming that arachidonic acid could have a crucial 
role in the pathology.  
Due to their amphipathic properties, naturally occurring PLs either 
from plant or animal origin, generally contain an unsaturated fatty 
acid in the sn-2 position, such as oleic acid, linoleic acid, α-linolenic 
acid, arachidonic acid (pro-inflammatory molecule usually from 
animal origin) or eicosapentaenoic acid (anti-inflammatory 
molecule usually from marine origin), whereas the sn-1 position 
predominantly carries a saturated fatty acid (SFA), such as stearic 
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acid or palmitic acid (Zhang et al., 2012).  
The correct ratio of saturated to unsaturated fatty acids in the 
phospholipid membrane is essential to sustain the membrane 
characteristics, since the fatty acid composition and degree of 
saturation directly affects the fluidity of the cell membrane.  
Even though the main function of PLs is to support the formation and 
biofunctionality of cell membranes.  
For example, PLs also contain bound PUFAs to be released on 
demand as precursors of prostaglandins and other eicosanoids 
(Tessaro et al., 2015), while other PLs and their metabolites are a 
source of secondary messengers in cell signalling (i.e., 
diacylglycerols, phosphoinositides, etc.) and carry out essential 
functions within organelles such as the mitochondria (Mejia et 
al.,2016; Choy et al.,2017). 
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7.MASS SPECTROMETRY: NEW TOOL 
IN PATHOLOGY RESEARCH 
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Mass spectrometric (MS) techniques are applied in various areas of 
medical diagnostics. Mass spectrometry provides unique 
advantages for the analysis of clinical specimens, and these 
capabilities have been critical to the advancement of diagnostic 
medicine. (Norris et al., 2013). Cells, whether bacterial, fungal or 
mammalian, are able to cover different metabolic pathways 
capable of producing an assortment of structurally and functionally 
distinct lipid species. The molecular mechanisms that are under this 
structural diversity remain poorly understood. In part, this is due to the 
lack of adequate analytical techniques capable of measuring the 
structural details of lipid species in a direct, comprehensive and 
quantitative manner. Today, increased understanding of the 
molecular basis of disease is revolutionizing the practice and delivery 
of health care. Analytical measurement of molecular markers has 
been a challenge of diagnostic medicine for many years and 
technologies for clinical measurements have significantly improved, 
adding increased throughput and sensitivity. These capabilities allow 
for the further development and validation of molecular markers for 
clinical use, provide important insights into the mechanism of disease 
that augment observations of tissue morphology. MS plays an 
important role due to the many advantages such as high sensitivity, 
wide dynamic range, molecular specificity, and the flexibility to 
address many varied analytes on a single platform. The impact of MS 
on diagnostic medicine is unequivocally significant. In the last 
decade years, test for biomarkers of endocrine function and drugs of 
abuse in body fluids (for example serum, plasma, urine, etc.) are 
among those most commonly used in clinical laboratories.  Today, 
liquid chromatography mass spectrometry (LC-MS) is the platform 
most commonly used for diagnostics. LC-MS applied to targeted 
molecular species is the strategy most widely adopted by clinical 
laboratories for carrying out routine testing. The tecnique allows the 
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comprehensive characterization and quantification of molecular 
glycerophospholipid species, molecular diacylglycerol species, 
molecular sphingolipid species including ceramides, 
glycosphingolipids and inositol containing sphingolipids, and sterol 
lipids including cholesterol.  
However, LC-MS can be used to analyze samples in solution, making 
it difficult to adapt to the analysis of tissue sections including the lack 
of information that is necessary to relate the molecular 
measurements to specific populations of cells in the tissue. To this aim 
analysis matrix assisted laser-desorption/ ionization imaging mass 
spectrometry (MALDI IMS) provide a substantial throughput 
advantage over chromatography-based approaches.  
MALDI IMS allows the localization of the analytes in the tissue as well 
as histology-directed experiments because the tissue pathology is 
used to guide the mass spectrometry analysis.  
Because change in lipid metabolism represent the major factors in 
the development of cancer. (Rompp et al., 2013), imaging of lipids 
of cell in the tissues could provide unique inside information about 
the state of the disease as well as its perspectives for pathology 
research and practice (Sparvero et al., 2010).   
Rujoi et al have mapped PLs composition of mammalian eyes using 
MALDI-TOF.MS. Specifically, feasibility of direct in situ analysis of two 
relevant PLs classes, phosphatidylcholines (PCs) and sphingomyelins 
(SMs) were demonstrated (Rujoi et al., 2004).  
An interesting study was conducted by Kurabe et al to explore lipid 
metabolism of 34 human colorectal cancer tissues to identify a 
cancer specific phospholipid signature. 
They have identified a news biomarker, PC (16:0/16:1), in colorectal 
cancer using imaging mass spectrometry. Specifically, elevated 
levels of PC (16:0/16:1) expression were observed in the advanced 
123 
 
 
stage of CRC. In addition, imaging mass spectrometry allowed to 
localize PC (16:0/16:1) in the cancer region (Kurabe et al., 2013).  
In conclusion, it has been shown that histology-directed mass 
spectrometry measurements provide unique insight into clinical 
questions. The in situ analysis of PLs by MALDI-TOF MS offers a rapid 
and sensitive tool for the mapping of PLs in biological tissues. 
Histology images are routinely used by the pathologist to diagnose 
disease leading MALDI IMS to revolutionize the practice of 
anatomical pathology in the coming decade. The implementation 
of molecular information into molecular pathway databases or the 
integration of multidimensional and complex MALDI Imaging data 
into systems medicine tools makes MALDI Imaging a valuable tool for 
a deeper understanding of the complexity of tissue and disease 
(Aichler et al., 2015). 
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